WO2018150450A1 - Aminocoumarin compound, and aminocoumarin compound-containing resin particles - Google Patents

Aminocoumarin compound, and aminocoumarin compound-containing resin particles Download PDF

Info

Publication number
WO2018150450A1
WO2018150450A1 PCT/JP2017/005284 JP2017005284W WO2018150450A1 WO 2018150450 A1 WO2018150450 A1 WO 2018150450A1 JP 2017005284 W JP2017005284 W JP 2017005284W WO 2018150450 A1 WO2018150450 A1 WO 2018150450A1
Authority
WO
WIPO (PCT)
Prior art keywords
aminocoumarin compound
compound
aminocoumarin
resin particles
formula
Prior art date
Application number
PCT/JP2017/005284
Other languages
French (fr)
Japanese (ja)
Inventor
健作 高梨
中山 慎
Original Assignee
コニカミノルタ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コニカミノルタ株式会社 filed Critical コニカミノルタ株式会社
Priority to PCT/JP2017/005284 priority Critical patent/WO2018150450A1/en
Priority to US16/477,433 priority patent/US11434376B2/en
Priority to JP2018568516A priority patent/JP7151489B2/en
Priority to EP18754496.0A priority patent/EP3553136A4/en
Priority to PCT/JP2018/004803 priority patent/WO2018151072A1/en
Publication of WO2018150450A1 publication Critical patent/WO2018150450A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09BORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B57/00Other synthetic dyes of known constitution
    • C09B57/02Coumarine dyes
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials

Definitions

  • the present invention relates to an aminocoumarin compound which is a novel pigment and aminocoumarin compound-encapsulating resin particles obtained by encapsulating the aminocoumarin compound in a resin.
  • the antigen is fluorescently labeled by specifically binding a fluorescently labeled antibody to an in vivo molecule (antigen) whose expression level increases or decreases depending on the presence or absence of the disease. The quantity is quantified.
  • CCR4 Inspection As an example of a recent clinical test developed to provide an indication of whether to administer to adult T-cell leukemia (ATL), the target of CCR4 Inspection to perform detection was required.
  • the detection of CCR4 has been developed by FACS method for immune reaction to collected blood samples and IHC method for immune reaction to collected tissue samples.
  • the former quantifies (scores) CCR4 by fluorescence detection
  • the latter quantifies (scores) CCR4 by color detection.
  • the need to obtain a lot of information at one time is not limited to immunohistochemical methods, and there is a strong need for medical personnel, and many methods for detecting different targets simultaneously with a plurality of fluorescent dyes are being developed. For example, preparing dyes that exhibit fluorescence in each of the green region, red region, orange region, and far-infrared region, and detecting four types of targets is possible in addition to the FACS method using the above immune reaction.
  • the ELISA method and the FISH method can be used and commercialized.
  • a sulfonated coumarin dye is known as a dye emitting in the green region.
  • the sulfonated coumarin dye include sulfonated coumarin dyes described in Patent Document 1. Since sulfonated coumarin dyes have excellent solubility in water, they are adaptable to fluorescence detection tools based on various immune reactions. However, on the other hand, the fluorescence noise derived from the specimen as described below has been a major factor for inaccurate fluorescence detection and quantification.
  • the present invention is intended to solve the problems associated with the prior art as described above, and a sulfonated coumarin dye having a maximum wavelength of an excitation spectrum in a wavelength region of 475 nm or more, for example, a wavelength region of 475 to 510 nm.
  • the purpose is to provide.
  • the aminocoumarin compound of the present invention has a structure represented by the following formula (1).
  • each R independently represents a hydrogen atom or a methyl group
  • Q represents a sulfur atom, an oxygen atom or N—R 1
  • R 1 represents a hydrogen atom or a methyl group.
  • the aminocoumarin compound is an aminocoumarin compound in which Q in the formula (1) is a sulfur atom, an aminocoumarin compound that is an oxygen atom, or an aminocoumarin compound that is N—R 1 .
  • the aminocoumarin compound-encapsulating resin particles of the present invention have the aminocoumarin compound and resin particles that encapsulate the aminocoumarin compound.
  • the resin particles are preferably amino resin particles.
  • the aminocoumarin compound-containing resin particles preferably have an excitation spectrum maximum wavelength of 475 to 510 nm and a fluorescence spectrum maximum wavelength of 510 to 540 nm.
  • the aminocoumarin compound of the present invention has an excitation wavelength longer than that of the conventionally known sulfonated coumarin compound described in Patent Document 1, and has a wavelength of 475 or more, particularly about 500 nm. It is a fluorescent dye that is effectively excited.
  • the aminocoumarin compound of the present invention is a fluorescent dye that can be excited in the wavelength range of 475 to 510 nm and observed in the green light emission region of 510 to 540 nm by utilizing this wavelength characteristic. It can be expected to be used appropriately.
  • the aminocoumarin compound of the present invention has a structure represented by the following formula (1).
  • R's each independently represent a hydrogen atom or a methyl group.
  • Q represents a sulfur atom, an oxygen atom or N—R 1 .
  • R 1 represents a hydrogen atom or a methyl group.
  • the aminocoumarin compound of the present invention has a benzothiazole structure when Q in formula (1) is a sulfur atom, has a benzoxazole structure when Q is an oxygen atom, and has benzoxazole structure when it is N—R 1. It will have an imidazole structure.
  • the sulfonic acid group SO 3 H contained in the formula (1) is bonded to any of the four carbon atoms that can be bonded to the benzene ring contained in the benzothiazole structure, benzoxazole structure or benzimidazole structure. May be.
  • the nitrogen atom bonded to the coumarin structure forms two 6-membered rings together with the four carbon atoms of the benzene ring contained in the coumarin structure, that is, the amino group of aminocoumarin is
  • the structure is different from known sulfonated coumarin compounds described in Patent Document 1 and the like in that it has a julolidine structure.
  • the aminocoumarin compound of the present invention having such a structure has an excitation wavelength longer than that of a known sulfonated coumarin compound, and has an excitation spectrum maximum wavelength of 475 nm or more, for example, 475 to 510 nm.
  • the aminocoumarin compound of the present invention has a longer emission wavelength than known sulfonated coumarin compounds, and has a maximum fluorescence spectrum wavelength of 510 nm or more, for example, 510 to 540 nm.
  • the “excitation spectrum maximum wavelength” means a wavelength exhibiting a maximum in the excitation spectrum.
  • “Fluorescence spectrum maximum wavelength” means a wavelength exhibiting a maximum in a fluorescence spectrum.
  • the aminocoumarin compound of the present invention represented by the formula (1) has a feature that the emission intensity is higher than that of an aminocoumarin compound formed by substituting the sulfone group of the aminocoumarin compound with a hydrogen atom.
  • the aminocoumarin compound of the present invention can be produced, for example, by a method of sulfonating a coumarin compound having a structure represented by the following formula (2). Specifically, the aminocoumarin compound of the present invention is produced by adding 1 ml of fuming sulfuric acid to 0.1 g of the coumarin compound represented by the formula (2) and reacting at 0 to 140 ° C. for 1 to 8 hours. be able to.
  • the aminocoumarin compound-encapsulating resin particles of the present invention have the aminocoumarin compound and resin particles that encapsulate the aminocoumarin compound.
  • the aminocoumarin compound-encapsulating resin particles of the present invention can be suitably used for immunostaining and the like.
  • the aminocoumarin compound encapsulated in the resin particles is as described above.
  • the resin particles encapsulating the aminocoumarin compound are not particularly limited as long as the aminocoumarin compound can be encapsulated, but is preferably a thermosetting resin. Since the thermosetting resin has a three-dimensional network structure, the dye encapsulated in the thermosetting resin is not easily detached from the resin particles, and is suitable for immunostaining and the like.
  • the thermosetting resin include melamine resin, urea resin, aniline resin, guanamine resin, phenol resin, xylene resin, and furan resin.
  • amino resins such as melamine resin and urea resin are particularly preferable because they can more effectively suppress the release of the pigment from the resin particles.
  • the amount of the aminocoumarin compound encapsulated in the resin particles is not particularly limited, and when the aminocoumarin compound-encapsulated resin particles are used for immunostaining, it may be an amount that can ensure a detectable luminance.
  • the average particle diameter of the aminocoumarin compound-encapsulating resin particles is not particularly limited, but when used for immunostaining, it is usually 40 to 500 nm, preferably 50 to 200 nm. If the average particle size of the aminocoumarin compound-encapsulating resin particles exceeds 500 nm, there may be a problem with dyeability, and if it is less than 40 nm, there may be a problem with visibility.
  • the average particle diameter is calculated as an average value obtained by measuring the particle diameter of 1000 aminocoumarin compound-encapsulated particles by SEM observation.
  • aminocoumarin compound-encapsulating resin particles of the present invention can be produced according to known methods for producing dye-encapsulating resin particles.
  • the aminocoumarin compound-encapsulating resin particles of the present invention can be produced by polymerizing a monomer raw material for resin synthesis in the presence of an aminocoumarin compound. Specifically, a monomer raw material for resin synthesis is added to an aqueous solution containing an aminocoumarin compound and a surfactant, and usually at 55 to 75 ° C., preferably 68 to 72 ° C., for about 10 minutes, preferably 10 to 15 Stir vigorously for minutes. Thereafter, a polymerization initiator is added, and emulsion polymerization is carried out by stirring vigorously at 55 to 75 ° C., preferably 68 to 72 ° C. for 4 to 24 hours, preferably 4 to 5 hours.
  • the liquid temperature is raised to 80 to 90 ° C., preferably 80 to 82 ° C., and the mixture is vigorously stirred for 30 to 60 minutes, preferably 30 to 40 minutes.
  • the reaction solution is usually divided into agglomerates and a particle dispersion as a supernatant.
  • the particle dispersion is recovered from the reaction solution.
  • This particle dispersion is centrifuged to remove the dispersion medium that is a supernatant, and then ultrapure water is added to the precipitate for ultrasonic dispersion.
  • the steps of centrifugation, addition of ultrapure water to the precipitate, and ultrasonic dispersion are repeated several more times. As a result, an aqueous dispersion of aminocoumarin compound-encapsulating resin particles is obtained.
  • the monomer raw material for resin synthesis is a raw material capable of forming the resin particles by polymerization.
  • the amount of aminocoumarin compound added is usually 1 to 50 mg with respect to 1 g of monomer raw material for resin synthesis.
  • the surfactant is not particularly limited, and a surfactant that is used in a usual emulsion polymerization reaction can be used.
  • a surfactant that is used in a usual emulsion polymerization reaction can be used.
  • all anionic, nonionic and cationic surfactants can be used.
  • the anionic surfactant include sodium dodecylbenzenesulfonate.
  • nonionic surfactants include polyethylene glycol and polyoxyethylene alkyl ether.
  • Examples of the cationic surfactant include dodecyltrimethylammonium bromide.
  • Surfactant may be used individually by 1 type, or may use 2 or more types together.
  • Emulgen registered trademark, manufactured by Kao Corporation
  • Neoperex registered trademark, manufactured by Kao Corporation
  • the active ingredient of emulgen is polyoxyethylene alkyl ether
  • the active ingredient of neoperex is sodium dodecylbenzenesulfonate.
  • the addition amount of the surfactant is usually 1 to 3 mg per 1 g of the monomer raw material for resin synthesis.
  • polymerization initiator examples include thermal polymerization initiators such as azo compounds and peroxides that generate radicals by heat.
  • V-50 (2,2′-Azobis (2-methylpropionamide) dihydrochloride is preferred as the azo compound.
  • the peroxide is preferably ammonium persulfate.
  • the polymerization initiator may be a redox polymerization initiator.
  • the addition amount of the polymerization initiator is usually 0.1 to 1.5 mg, preferably 0.3 to 0.45 mg per 1 g of the monomer raw material for resin synthesis.
  • the resin particles are preferably amino resin particles.
  • the aminocoumarin compound-containing resin particles preferably have an excitation spectrum maximum wavelength of 475 to 510 nm and a fluorescence spectrum maximum wavelength of 510 to 540 nm.
  • the aminocoumarin compound-encapsulating resin particle of the present invention produced by encapsulating the aminocoumarin compound represented by the formula (1) in the resin is formed by substituting the sulfo group of the aminocoumarin compound with a hydrogen atom.
  • the emission intensity tends to be strong. This is because the aminocoumarin compound represented by the formula (1) is more easily included in the resin than the aminocoumarin compound formed by replacing the sulfone group of the aminocoumarin compound with a hydrogen atom. It is presumed that it is taken in.
  • Example 1 In a 20 mL vial tube, 600 mg of the compound (3) represented by the following formula (3) was added, 6 mL of fuming sulfuric acid was added, and the mixture was stirred at 25 ° C. for 4 hours to carry out the reaction. Progress of the reaction was confirmed by TLC. Specifically, a part of the reaction solution was neutralized with an aqueous NaOH solution, ethanol was added to the reaction solution, and TLC was performed using a solution in which CHCl 3 was mixed at a ratio of 2 and MeOH at a ratio of 3. The Rf value of the target product was 0.73 against the Rf value of 0.88 of the raw material, and the convergence of the reaction and the generation of the target product were confirmed from the TLC data.
  • the recovered precipitate was dispersed with ethanol, the dispersion was centrifuged, and the supernatant was removed to obtain an aminocoumarin compound I represented by the following formula (I) as a precipitate.
  • the yield of aminocoumarin compound I was 80%.
  • the obtained powder was added to pure water, then neutralized with an aqueous NaOH solution to dissolve the precipitate, and the pH of the solution was adjusted to 7-8.
  • This solution was dried with a freeze dryer to obtain Na salt of aminocoumarin compound I. It was confirmed that the aminocoumarin compound I dissolves quickly in water by using Na salt, whereas the sulfonic acid form has poor solubility in water.
  • the aminocoumarin compound I was dissolved in a solvent obtained by mixing double distilled water (DDW) 10 and ethanol at a ratio of 1 to prepare a 10 nM solution.
  • the fluorescence intensity at the excitation spectrum maximum wavelength, the fluorescence spectrum maximum wavelength, and the excitation wavelength 490 nm was measured for this solution using a spectrofluorophotometer F-7000 (manufactured by Hitachi, Ltd.). The results are shown in Table 1.
  • the excitation spectrum was measured by fixing the fluorescence wavelength to be detected and scanning the wavelength of the excitation light. In the fluorescence spectrum, the fluorescence intensity was measured with the wavelength of excitation light fixed.
  • Example 2 An aminocoumarin compound II represented by the following formula (II) was prepared in the same manner as in Example 1 except that the compound (4) represented by the following formula (4) was used instead of the compound represented by the formula (3). Got. The yield of aminocoumarin compound II was 82%.
  • Example 3 The aminocoumarin compound III represented by the following formula (III) was prepared in the same manner as in Example 1 except that the compound (5) represented by the following formula (5) was used instead of the compound represented by the formula (3). Got. The yield of aminocoumarin compound III was 80%.
  • Excitation spectrum maximum wavelength and fluorescence spectrum maximum wavelength were measured in the same manner as in Example 1 using aminocoumarin compound III. The results are shown in Table 1.
  • Example 4 The aminocoumarin compound IV represented by the following formula (IV) was prepared in the same manner as in Example 1 except that the compound (6) represented by the following formula (6) was used instead of the compound represented by the formula (3). Got. The yield of aminocoumarin compound IV was 75%.
  • Example 5 The aminocoumarin compound V represented by the following formula (V) was prepared in the same manner as in Example 1 except that the compound (7) represented by the following formula (7) was used instead of the compound represented by the formula (3). Got. The yield of aminocoumarin compound V was 70%.
  • Example 6 The aminocoumarin compound VI represented by the following formula (VI) was prepared in the same manner as in Example 1 except that the compound (8) represented by the following formula (8) was used instead of the compound represented by the formula (3). Got. The yield of aminocoumarin compound VI was 75%.
  • Example 7 14.4 mg of aminocoumarin compound I was added to 22 mL of water and dissolved. To this solution, 2 mL of a 5% aqueous solution of an emulsion (registered trademark) 430 (polyoxyethylene oleyl ether, manufactured by Kao Corporation) of an emulsifier for emulsion polymerization was added.
  • an emulsion (registered trademark) 430 polyoxyethylene oleyl ether, manufactured by Kao Corporation
  • the solution was heated to 70 ° C. while stirring on a hot stirrer, and then 0.65 g of melamine resin raw material Nicalak MX-035 (manufactured by Nippon Carbide Industries Co., Ltd.) was added to the solution.
  • melamine resin raw material Nicalak MX-035 manufactured by Nippon Carbide Industries Co., Ltd.
  • To this solution was added 1000 ⁇ L of a 10% aqueous solution of dodecylbenzenesulfonic acid (manufactured by Kanto Chemical Co., Ltd.) as a reaction initiator, and the mixture was heated and stirred at 70 ° C. for 50 minutes, then heated to 90 ° C. and stirred for 20 minutes.
  • aminocoumarin compound-encapsulating resin particles I were obtained.
  • the resulting dispersion of aminocoumarin compound-encapsulating resin particles I was washed with pure water to remove excess resin raw materials and impurities such as aminocoumarin compounds. Specifically, the mixture was centrifuged at 20000 G for 15 minutes in a centrifuge (Kubota Micro Cooling Centrifuge 3740), and after removing the supernatant, ultrapure water was added and ultrasonically irradiated to redisperse. Centrifugation, supernatant removal, and washing by redispersion in ultrapure water were repeated 5 times.
  • the average particle size of the aminocoumarin compound-encapsulating resin particles I was calculated from the particle diameter of the SEM image. The results are shown in Table 2.
  • Aminocoumarin compound-encapsulating resin particle I is diluted to 0.0189 mg / mL, 100 uL is taken, put into a fluorescence microcell, and using a spectrofluorometer F-7000 (manufactured by Hitachi, Ltd.) at an excitation wavelength of 490 nm. The fluorescence intensity was measured. The results are shown in Table 2.
  • the aminocoumarin compound-encapsulating resin particles I were subjected to the following FACS (Fluorescence Activated Cell Sorting) and FISH (Fluorescence in situ hybridization).
  • FACS evaluation Maleimide was introduced into the end of the aminocoumarin compound-encapsulating resin particle I using NHS-PEG (polyethylene glycol) -maleimide reagent, and a thiolated anti-HER2 antibody was bound thereto.
  • the frozen cells of COLO201 obtained from ATCC are thawed in a 37 ° C constant temperature bath, and about 1 ⁇ 10 5 cells / mL are suspended in the medium, and the first culture is performed in a 25 cm 2 flask. Carried out. Trypsinize the culture medium with about 1 ⁇ 10 6 cells / mL and dilute a part of the cells detached from the flask with Cell bunker solution (10% DMSO). did. The remaining cells were subcultured and cultured to a target amount of about 5 ⁇ 10 7 cells. After floating and recovering with a scraper, a part was used for FACS measurement.
  • HER2 protein present on the surface of cultured cells was measured with FACSCalibur (trade name; manufactured by Becton Dickinson).
  • FACSCalibur (trade name; manufactured by Becton Dickinson).
  • a mixture of the PBS solution of aminocoumarin compound-encapsulating resin particles I and COLO201 cultured as described above was incubated at 4 ° C. for 30 minutes, 100 ⁇ l of the mixture was taken into a measuring tube, and Assay Diluent (trade name, Becton It was diluted to 2 ml with Deckson Corporation and injected into FACSCalibur.
  • the results are shown in Table 2.
  • the diagram shown as a result of FACS in Table 2 is a histogram with the horizontal axis representing the fluorescence intensity of 530 nm by 490 nm excitation light and the vertical axis representing the count number.
  • the fluorescence intensity is stronger, that is, brighter as the histogram is shifted to the right side.
  • the result of Example 7 is shown in comparison with the result of Comparative Example 5 using the following aminocoumarin compound-encapsulating resin particles i. The same applies to other examples and comparative examples 6 to 8.
  • a histogram having a peak near the fluorescence intensity 90 is the histogram of Comparative Example 5
  • a histogram having a peak near the fluorescence intensity 500 is the histogram of Example 7. It can be seen that the histogram of Example 7 is considerably shifted to the right from the histogram of Comparative Example 5. From this result, it can be seen that the aminocoumarin compound-encapsulating resin particles I of Example 7 have a stronger fluorescence intensity and brighter than the aminocoumarin compound-encapsulating resin particles i of Comparative Example 5.
  • FISH evaluation [Preparation of BAC probe] CellBiochemBiophys. In accordance with the method described in 2006; 45 (1) 59, a nucleic acid molecule was prepared as follows.
  • dTTP of the HER2 DNA clone was replaced with DNP-labeled dUTP by the nick translation method.
  • a solution containing 25 ⁇ L (concentration 1 ⁇ g / 250 ⁇ L) of a DNP-labeled BAC probe by nick translation and 1.0 ⁇ L (50 nmol / 50 ⁇ L) of aminocoumarin compound-encapsulating resin particles surface-modified with an anti-DNP antibody was mixed to room temperature. Then, a binding reaction was performed for 30 minutes to obtain a DNA probe reagent for HER-2 detection.
  • Hybridization buffer (25% deionized formamide, 2 ⁇ SSC, 200 ng / ⁇ L salmon sperm DNA, 5 ⁇ Denhardt's solution, 50 mM sodium phosphate, pH 7.0, 1 mM EDTA) Diluted to a final concentration of 1-5 ng / ⁇ L. If necessary, free ligand was removed with an S300 size spin column (Amersham Biosciences, Piscataway, NJ). If not used immediately, the DNA probe was stored frozen at -20 ° C.
  • FISH includes deparaffinization, specimen slide pretreatment, enzyme treatment, specimen fixing treatment, probe preparation, specimen slide DNA denaturation treatment, hybridization treatment, slide glass washing treatment, and DAPI. The staining process was performed in this order.
  • Deparaffinization was performed by treating a specimen slide of a HER2-positive stained control specimen (“HER2-FISH Control Slide Code PS-09006” manufactured by Pathology Laboratories) in the order of (1) to (4) below. .
  • HER2-FISH Control Slide Code PS-09006 manufactured by Pathology Laboratories
  • (1) Immerse in Hemo-De for 10 minutes at room temperature.
  • (2) Immerse the specimen slide in new Hemo-De for 10 minutes at room temperature. Repeat the same operation three times.
  • the specimen slide is immersed in 100% ethanol at room temperature for 5 minutes, washed twice, and dehydrated.
  • the specimen slide is air-dried or dried on a slide warmer at 45 to 50 ° C.
  • the specimen slide was pretreated in the following order (1) to (6) to remove proteins from the cell membrane and the nuclear membrane.
  • (1) Treat the specimen slide with 0.2 mol / L HCl at room temperature for 20 minutes.
  • (2) Immerse the specimen slide in purified water for 3 minutes.
  • (3) The specimen slide is immersed in a washing buffer solution (2 ⁇ SSC: standard saline citrate) for 3 minutes.
  • (4) The specimen slide is immersed in a pretreatment solution (1N NaSCN) at 80 ° C. for 30 minutes.
  • (6) The specimen slide is immersed in a washing buffer solution (2 ⁇ SSC) for 5 minutes, and this immersion operation is repeated twice.
  • the sample treatment that had been pretreated was subjected to enzyme treatment by performing the following treatments (1) to (4) in this order.
  • (2) The specimen slide is immersed in a protease solution heated to 37 ° C. for 10 to 60 minutes. This immersion treatment is performed with 25 mg protease (2500-3000 Units / mg) [pepsin] / 1M NaCl [pH 2.0] in 50 mL at 37 ° C. for 60 minutes) in order to decompose cell membrane and nuclear membrane proteins, particularly collagen. It is desirable to process.
  • (4) The specimen slide is air-dried or dried on a slide warmer at 45 to 50 ° C. for 2 to 5 minutes.
  • specimen fixation As the specimen fixing process, the following processes (1) to (3) were performed on the specimen slide that had been pretreated.
  • the specimen slide is immersed in 10% neutral buffered formalin (“4% paraformaldehyde / phosphate buffer” manufactured by Wako Pure Chemical Industries, Ltd., product number 163-1004) at room temperature for 10 minutes.
  • 10% neutral buffered formalin (“4% paraformaldehyde / phosphate buffer” manufactured by Wako Pure Chemical Industries, Ltd., product number 163-1004)
  • the specimen slide is air-dried or dried on a slide warmer at 45 to 50 ° C. for 2 to 5 minutes.
  • DAPI staining was performed as follows. First, 10 ⁇ L of DAPI counterstain was added to the hybridization area of the specimen slide. Next, after hybridization treatment, DAPI staining (2 ⁇ g / mL PBS) is performed at 25 ° C. for 10 minutes in order to count the number of cells. The cell nucleus is stained, covered with a cover glass, and the specimen slide is covered until signal measurement. Stored protected from light. DAPI (4 ′, 6-Diamidino-2-phenylindole, Dihydrochloride) used Molecular Probes (D1306).
  • Table 2 shows the result of measuring the number of bright spots from the obtained fluorescence image.
  • the difference in the number of measured starting points was observed in the comparative example, while it was relatively difficult to find the green bright spot (signal) from the green background (noise). This is because in the case of the example, since the luminance is high, detection can be performed without being affected by noise.
  • aminocoumarin compound-encapsulating resin particles II to VI were prepared in the same manner as in Example 7 except that aminocoumarin compounds II to VI were used in place of aminocoumarin compound I, respectively.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides: an aminocoumarin compound having a structure represented by formula (1); and aminocoumarin compound-containing resin particles which include the aminocoumarin compound, and resin particles containing the aminocoumarin compound. In formula (1): each R independently represents hydrogen or a methyl group; Q represents sulfur, oxygen, or N-R1; and R1 represents hydrogen or a methyl group. This aminocoumarin compound is a fluorescent dye which has a longer excitation wavelength than sulfonated coumarin compounds well known in the prior art, and is effectively excited at wavelengths equal to or longer than 475 nm, particularly wavelengths in the vicinity of 500 nm. This aminocoumarin compound is a fluorescent dye which has wavelength characteristics that can used to perform excitation at wavelengths in the range of 475-510 nm, and enable observation in the green light emission region of 510-540 nm. It is anticipated that the aminocoumarin compound will be suitably utilized in immunostaining or the like.

Description

アミノクマリン化合物およびアミノクマリン化合物内包樹脂粒子Aminocoumarin compounds and aminocoumarin compound-containing resin particles
 本発明は、新規な色素であるアミノクマリン化合物およびこのアミノクマリン化合物を樹脂に内包してなるアミノクマリン化合物内包樹脂粒子に関する。 The present invention relates to an aminocoumarin compound which is a novel pigment and aminocoumarin compound-encapsulating resin particles obtained by encapsulating the aminocoumarin compound in a resin.
 現在の医療環境においては、被験者が対象疾患に罹患しているか否かを判断するためのデータを提供するために、あるいは被験者へ投薬すべきかどうかの指標を提供するために、さまざまな臨床用検査薬や研究用検査薬が開発され、治療の大きな助けとなっている。被験者から血液や組織切片等の検体を採取し、多くの場合には免疫反応を利用して特定のターゲット(低分子・タンパク・遺伝子・細胞など)を検出し、同定し、定量することで、さまざまな検査が開発されてきた。例えば、前記罹患の有無によって発現量が増減する生体内の分子(抗原)に、蛍光標識した抗体を特異的に結合させることにより抗原を蛍光標識し、蛍光シグナルの量から疾患に関連する抗原の量を定量することが行われる。また、成人T細胞白血病 (ATL)へ投薬すべきかどうかの指標を提供するために開発された最近の臨床用検査薬の例として、抗 CCR4 抗体モガムリズマブ分子標的薬の投与前にターゲットであるCCR4の検出を行う検査が義務づけられた。CCR4の検出は、採取した血液検体に免疫反応を施すFACS法と、採取した組織検体に免疫反応を施すIHC法とが開発されており、前者は蛍光検出によりCCR4を定量(スコア化)し、後者は発色検出によりCCR4を定量(スコア化)している。ところで、採取した組織検体に免疫反応を施す免疫組織化学的手法の中にも、蛍光標識した抗体を抗原に結合させる技術も知られており、蛍光色素を粒子に内包させたナノ粒子に抗体を直接的または間接的に結合させ、これを抗原に結合させる技術が高感度達成に有用と考えられている。 In the current medical environment, a variety of clinical tests are available to provide data for determining whether a subject is affected by the disease or to provide an indication of whether the subject should be dosed. Drugs and laboratory test drugs have been developed and have greatly helped the treatment. By collecting specimens such as blood and tissue sections from subjects, in many cases using immune responses to detect, identify, and quantify specific targets (small molecules, proteins, genes, cells, etc.) Various tests have been developed. For example, the antigen is fluorescently labeled by specifically binding a fluorescently labeled antibody to an in vivo molecule (antigen) whose expression level increases or decreases depending on the presence or absence of the disease. The quantity is quantified. In addition, as an example of a recent clinical test developed to provide an indication of whether to administer to adult T-cell leukemia (ATL), the target of CCR4 Inspection to perform detection was required. The detection of CCR4 has been developed by FACS method for immune reaction to collected blood samples and IHC method for immune reaction to collected tissue samples.The former quantifies (scores) CCR4 by fluorescence detection, The latter quantifies (scores) CCR4 by color detection. By the way, among immunohistochemical techniques for performing an immune reaction on a collected tissue specimen, a technique for binding a fluorescently labeled antibody to an antigen is also known. A technique of binding directly or indirectly and binding it to an antigen is considered useful for achieving high sensitivity.
 免疫組織化学的手法に限らず、一度に多くの情報を得たいというニーズは医療関係者に強くあり、複数の蛍光色素で同時に別のターゲットを検出する方法の開発も多く進められている。たとえば、緑色領域、赤色領域、オレンジ色領域および遠赤外線領域の各領域において蛍光発光を呈する色素を用意して、4種類のターゲットを検出することは上記の免疫反応を利用するFACS法の他にもELISA法、FISH法などで原理的には可能であり、商品化もされている。 The need to obtain a lot of information at one time is not limited to immunohistochemical methods, and there is a strong need for medical personnel, and many methods for detecting different targets simultaneously with a plurality of fluorescent dyes are being developed. For example, preparing dyes that exhibit fluorescence in each of the green region, red region, orange region, and far-infrared region, and detecting four types of targets is possible in addition to the FACS method using the above immune reaction. In principle, the ELISA method and the FISH method can be used and commercialized.
 緑色領域で発光する色素としては、スルホン化されたクマリン系色素が知られている。このスルホン化クマリン色素としては、たとえば特許文献1に記載されたスルホン化クマリン色素が挙げられる。スルホン化クマリン色素は、水への溶解性が優れるので、さまざまな免疫反応による蛍光検出ツールに対する適応性がある。しかしその一方、以下の通り検体に由来する蛍光ノイズが、蛍光検出および定量を不正確にする大きな要因になっていた。 A sulfonated coumarin dye is known as a dye emitting in the green region. Examples of the sulfonated coumarin dye include sulfonated coumarin dyes described in Patent Document 1. Since sulfonated coumarin dyes have excellent solubility in water, they are adaptable to fluorescence detection tools based on various immune reactions. However, on the other hand, the fluorescence noise derived from the specimen as described below has been a major factor for inaccurate fluorescence detection and quantification.
 たとえば緑の蛍光発光を示す色素の場合、スルホン化クマリン色素については、そのほとんどは470nm以下の波長領域に励起スペクトルの極大波長を有し、475nm以上の波長では励起光吸収が大幅に低減する。このため、従来のスルホン化クマリン色素は、多重染色を行う上で別の蛍光色素の波長領域から影響を受けてしまうなどの制約が大きい。 For example, in the case of a dye exhibiting green fluorescence, most of the sulfonated coumarin dyes have the maximum wavelength of the excitation spectrum in the wavelength region of 470 nm or less, and the absorption of the excitation light is significantly reduced at a wavelength of 475 nm or more. For this reason, conventional sulfonated coumarin dyes are greatly limited in that they are affected by the wavelength region of another fluorescent dye when performing multiple staining.
 また、475nmより短波長領域では、当該蛍光色素以外の物質(夾雑物)に起因する蛍光、いわゆる自家蛍光が大きくなる傾向がある。このため、従来のスルホン化クマリン色素を用いた免疫蛍光検出においては、蛍光色素に基づく蛍光強度に対して、バックグラウンドの蛍光強度が相対的に高くなり、シグナル/バックグラウンド比(S/B)が低くなるという問題があった。 Also, in the wavelength region shorter than 475 nm, fluorescence caused by substances (contaminants) other than the fluorescent dye, so-called autofluorescence tends to increase. For this reason, in the conventional immunofluorescence detection using a sulfonated coumarin dye, the background fluorescence intensity is relatively higher than the fluorescence intensity based on the fluorescent dye, and the signal / background ratio (S / B) There was a problem that became low.
特開平6-271599号公報JP-A-6-271599
 本発明は、上記のような従来技術に伴う問題を解決しようとするものであって、475nm以上の波長領域、たとえば475~510nmの波長領域に励起スペクトルの極大波長を有するスルホン化クマリン系色素を提供することを目的とする。 The present invention is intended to solve the problems associated with the prior art as described above, and a sulfonated coumarin dye having a maximum wavelength of an excitation spectrum in a wavelength region of 475 nm or more, for example, a wavelength region of 475 to 510 nm. The purpose is to provide.
 本発明者らは、上記問題点を解決すべく鋭意研究した結果、特定構造を有するアミノクマリン化合物が上記の課題を解決できることを見出し、本発明を完成するに至った。 As a result of intensive studies to solve the above problems, the present inventors have found that an aminocoumarin compound having a specific structure can solve the above problems, and have completed the present invention.
 すなわち、本発明のアミノクマリン化合物は、下記式(1)で示される構造を有する。 That is, the aminocoumarin compound of the present invention has a structure represented by the following formula (1).
Figure JPOXMLDOC01-appb-C000002
(式(1)中、Rは、それぞれ独立に水素原子またはメチル基を表わし、Qはイオウ原子、酸素原子またはN-R1を表わし、R1は水素原子またはメチル基を表わす。)
 前記アミノクマリン化合物は、前記式(1)中のQがイオウ原子であるアミノクマリン化合物、酸素原子であるアミノクマリン化合物、またはN-R1であるアミノクマリン化合物である。
Figure JPOXMLDOC01-appb-C000002
(In formula (1), each R independently represents a hydrogen atom or a methyl group, Q represents a sulfur atom, an oxygen atom or N—R 1 , and R 1 represents a hydrogen atom or a methyl group.)
The aminocoumarin compound is an aminocoumarin compound in which Q in the formula (1) is a sulfur atom, an aminocoumarin compound that is an oxygen atom, or an aminocoumarin compound that is N—R 1 .
 本発明のアミノクマリン化合物内包樹脂粒子は、前記アミノクマリン化合物と該アミノクマリン化合物を内包する樹脂粒子とを有する。 The aminocoumarin compound-encapsulating resin particles of the present invention have the aminocoumarin compound and resin particles that encapsulate the aminocoumarin compound.
 前記アミノクマリン化合物内包樹脂粒子において、前記樹脂粒子がアミノ樹脂粒子であることが好ましい。 In the aminocoumarin compound-encapsulating resin particles, the resin particles are preferably amino resin particles.
 前記アミノクマリン化合物内包樹脂粒子は、励起スペクトル極大波長が475~510nmであり、蛍光スペクトル極大波長が510~540nmであることが好ましい。 The aminocoumarin compound-containing resin particles preferably have an excitation spectrum maximum wavelength of 475 to 510 nm and a fluorescence spectrum maximum wavelength of 510 to 540 nm.
 本発明のアミノクマリン化合物は、従来知られている特許文献1に記載のスルホン化クマリン系化合物等と比べ、励起波長がより長波長であり、475以上の波長、特に500nm近辺の波長に対して有効に励起する蛍光色素である。本発明のアミノクマリン化合物は、この波長特性を利用して、たとえば475~510nmの波長で励起をし、510~540nmの緑色発光領域において観察することが可能な蛍光色素であり、免疫染色等において好適に活用することが期待できる。 The aminocoumarin compound of the present invention has an excitation wavelength longer than that of the conventionally known sulfonated coumarin compound described in Patent Document 1, and has a wavelength of 475 or more, particularly about 500 nm. It is a fluorescent dye that is effectively excited. The aminocoumarin compound of the present invention is a fluorescent dye that can be excited in the wavelength range of 475 to 510 nm and observed in the green light emission region of 510 to 540 nm by utilizing this wavelength characteristic. It can be expected to be used appropriately.
 本発明のアミノクマリン化合物は、下記式(1)で示される構造を有する。 The aminocoumarin compound of the present invention has a structure represented by the following formula (1).
Figure JPOXMLDOC01-appb-C000003
 式(1)中、12個のRは、それぞれ独立に水素原子またはメチル基を表わす。
Figure JPOXMLDOC01-appb-C000003
In formula (1), 12 R's each independently represent a hydrogen atom or a methyl group.
 式(1)中、Qはイオウ原子、酸素原子またはN-R1を表わす。前記R1は水素原子またはメチル基を表わす。本発明のアミノクマリン化合物は、式(1)のQがイオウ原子である場合、ベンゾチアゾール構造を有し、酸素原子である場合、ベンゾオキサゾール構造を有し、N-R1である場合、ベンゾイミダゾール構造を有することになる。 In the formula (1), Q represents a sulfur atom, an oxygen atom or N—R 1 . R 1 represents a hydrogen atom or a methyl group. The aminocoumarin compound of the present invention has a benzothiazole structure when Q in formula (1) is a sulfur atom, has a benzoxazole structure when Q is an oxygen atom, and has benzoxazole structure when it is N—R 1. It will have an imidazole structure.
 式(1)に含まれるスルホン酸基SO3Hは、前記ベンゾチアゾール構造、ベンゾオキサゾール構造またはベンゾイミダゾール構造に含まれるベンゼン環が有する結合可能な4つの炭素原子のうちどの炭素原子に結合していてもよい。 The sulfonic acid group SO 3 H contained in the formula (1) is bonded to any of the four carbon atoms that can be bonded to the benzene ring contained in the benzothiazole structure, benzoxazole structure or benzimidazole structure. May be.
 本発明のアミノクマリン化合物は、クマリン構造に結合する窒素原子が、クマリン構造に含まれるベンゼン環の4つの炭素原子とともに、2つの6員環を形成している点、すなわちアミノクマリンのアミノ基がジュロリジン構造となっている点で、特許文献1などに記載された公知のスルホン化クマリン系化合物と構造が相違する。 In the aminocoumarin compound of the present invention, the nitrogen atom bonded to the coumarin structure forms two 6-membered rings together with the four carbon atoms of the benzene ring contained in the coumarin structure, that is, the amino group of aminocoumarin is The structure is different from known sulfonated coumarin compounds described in Patent Document 1 and the like in that it has a julolidine structure.
 このような構造を有する本発明のアミノクマリン化合物は、公知のスルホン化クマリン系化合物よりも、励起波長が長波長であり、励起スペクトル極大波長が475nm以上であり、たとえば475~510nmである。また、本発明のアミノクマリン化合物は、発光波長も公知のスルホン化クマリン系化合物より長波長であり、蛍光スペクトル極大波長が510nm以上であり、たとえば510~540nmである。ここで、「励起スペクトル極大波長」とは、励起スペクトルにおいて極大を示す波長を意味する。「蛍光スペクトル極大波長」とは、蛍光スペクトルにおいて極大を示す波長を意味する。 The aminocoumarin compound of the present invention having such a structure has an excitation wavelength longer than that of a known sulfonated coumarin compound, and has an excitation spectrum maximum wavelength of 475 nm or more, for example, 475 to 510 nm. The aminocoumarin compound of the present invention has a longer emission wavelength than known sulfonated coumarin compounds, and has a maximum fluorescence spectrum wavelength of 510 nm or more, for example, 510 to 540 nm. Here, the “excitation spectrum maximum wavelength” means a wavelength exhibiting a maximum in the excitation spectrum. “Fluorescence spectrum maximum wavelength” means a wavelength exhibiting a maximum in a fluorescence spectrum.
 式(1)で表わされる本発明のアミノクマリン化合物は、該アミノクマリン化合物のスルホン基を水素原子で置換して形成されるアミノクマリン化合物に比較して、発光強度が強いという特徴を有する。 The aminocoumarin compound of the present invention represented by the formula (1) has a feature that the emission intensity is higher than that of an aminocoumarin compound formed by substituting the sulfone group of the aminocoumarin compound with a hydrogen atom.
 本発明のアミノクマリン化合物は、たとえば、下記式(2)で示される構造を有するクマリン化合物をスルホン化する方法により製造することができる。具体的には、式(2)で示されるクマリン化合物0.1gに対して発煙硫酸を1ml加えて、0~140℃で、1~8時間反応させることにより本発明のアミノクマリン化合物を製造することができる。 The aminocoumarin compound of the present invention can be produced, for example, by a method of sulfonating a coumarin compound having a structure represented by the following formula (2). Specifically, the aminocoumarin compound of the present invention is produced by adding 1 ml of fuming sulfuric acid to 0.1 g of the coumarin compound represented by the formula (2) and reacting at 0 to 140 ° C. for 1 to 8 hours. be able to.
Figure JPOXMLDOC01-appb-C000004
(式(2)中のRおよびQは、それぞれ式(1)中のRおよびQと同義である。)
 本発明のアミノクマリン化合物内包樹脂粒子は、前記アミノクマリン化合物と該アミノクマリン化合物を内包する樹脂粒子とを有する。本発明のアミノクマリン化合物内包樹脂粒子は、免疫染色等に好適に使用することができる。
Figure JPOXMLDOC01-appb-C000004
(R and Q in formula (2) have the same meanings as R and Q in formula (1), respectively).
The aminocoumarin compound-encapsulating resin particles of the present invention have the aminocoumarin compound and resin particles that encapsulate the aminocoumarin compound. The aminocoumarin compound-encapsulating resin particles of the present invention can be suitably used for immunostaining and the like.
 樹脂粒子に内包されるアミノクマリン化合物については前述のとおりである。 The aminocoumarin compound encapsulated in the resin particles is as described above.
 アミノクマリン化合物を内包する樹脂粒子は、アミノクマリン化合物を内包できる限り特に制限はないが、 熱硬化性樹脂であることが好ましい。 熱硬化性樹脂は三次元的な網目構造を有するので、これに包み込まれた色素は樹脂粒子から離脱しにくく、免疫染色等において好適である。熱硬化性樹脂としては、メラミン樹脂、尿素樹脂、アニリン樹脂、グアナミン樹脂、フェノール樹脂、キシレン樹脂およびフラン樹脂等を挙げることができる。これらの中でも、メラミン樹脂、尿素樹脂等のアミノ樹脂は、色素の樹脂粒子からの離脱をより効果的に抑止できる点で、特に好ましい。 The resin particles encapsulating the aminocoumarin compound are not particularly limited as long as the aminocoumarin compound can be encapsulated, but is preferably a thermosetting resin. Since the thermosetting resin has a three-dimensional network structure, the dye encapsulated in the thermosetting resin is not easily detached from the resin particles, and is suitable for immunostaining and the like. Examples of the thermosetting resin include melamine resin, urea resin, aniline resin, guanamine resin, phenol resin, xylene resin, and furan resin. Among these, amino resins such as melamine resin and urea resin are particularly preferable because they can more effectively suppress the release of the pigment from the resin particles.
 樹脂粒子に内包されるアミノクマリン化合物の量は、特に制限はなく、アミノクマリン化合物内包樹脂粒子を免疫染色に用いる場合には、検出可能な輝度を確保できる量であればよい。 The amount of the aminocoumarin compound encapsulated in the resin particles is not particularly limited, and when the aminocoumarin compound-encapsulated resin particles are used for immunostaining, it may be an amount that can ensure a detectable luminance.
 アミノクマリン化合物内包樹脂粒子の平均粒径は、特に制限はないが、免疫染色に用いる場合には、通常40~500nm、好ましくは50~200nmである。アミノクマリン化合物内包樹脂粒子の平均粒径が500nmを超えると染色性に問題が生じる場合があり、40nm未満であると、視認性に問題が生じる場合がある。 The average particle diameter of the aminocoumarin compound-encapsulating resin particles is not particularly limited, but when used for immunostaining, it is usually 40 to 500 nm, preferably 50 to 200 nm. If the average particle size of the aminocoumarin compound-encapsulating resin particles exceeds 500 nm, there may be a problem with dyeability, and if it is less than 40 nm, there may be a problem with visibility.
 上記平均粒径は、SEM観察でアミノクマリン化合物内包粒子の1000個について粒径を測定し、その平均値として算出される。 The average particle diameter is calculated as an average value obtained by measuring the particle diameter of 1000 aminocoumarin compound-encapsulated particles by SEM observation.
 本発明のアミノクマリン化合物内包樹脂粒子は、公知の色素内包樹脂粒子の製造方法に準じて製造することができる。 The aminocoumarin compound-encapsulating resin particles of the present invention can be produced according to known methods for producing dye-encapsulating resin particles.
 たとえば、本発明のアミノクマリン化合物内包樹脂粒子は、樹脂合成用のモノマー原料をアミノクマリン化合物の存在下で重合させることにより製造することができる。具体的には、アミノクマリン化合物および界面活性剤を含有する水溶液に樹脂合成用のモノマー原料を添加し、通常55~75℃、好ましくは68~72℃で、10分間程度、好ましくは10~15分間激しく撹拌する。その後、重合開始剤を添加して、55~75℃、好ましくは68~72℃で、4~24時間、好ましくは4~5時間激しく撹拌して、乳化重合させる。さらに、液温を80~90℃、好ましくは80~82℃に上げ、30~60分間、好ましくは30~40分間激しく攪拌する。反応液は、通常、凝集塊と上清である粒子分散液とに分かれる。反応液から粒子分散液を回収する。この粒子分散液を遠心分離し、上清である分散媒を除いた後、沈殿に超純水を加え、超音波分散する。遠心分離、沈殿への超純水添加および超音波分散の工程をさらに数回繰り返す。これにより、アミノクマリン化合物内包樹脂粒子の水分散液が得られる。 For example, the aminocoumarin compound-encapsulating resin particles of the present invention can be produced by polymerizing a monomer raw material for resin synthesis in the presence of an aminocoumarin compound. Specifically, a monomer raw material for resin synthesis is added to an aqueous solution containing an aminocoumarin compound and a surfactant, and usually at 55 to 75 ° C., preferably 68 to 72 ° C., for about 10 minutes, preferably 10 to 15 Stir vigorously for minutes. Thereafter, a polymerization initiator is added, and emulsion polymerization is carried out by stirring vigorously at 55 to 75 ° C., preferably 68 to 72 ° C. for 4 to 24 hours, preferably 4 to 5 hours. Further, the liquid temperature is raised to 80 to 90 ° C., preferably 80 to 82 ° C., and the mixture is vigorously stirred for 30 to 60 minutes, preferably 30 to 40 minutes. The reaction solution is usually divided into agglomerates and a particle dispersion as a supernatant. The particle dispersion is recovered from the reaction solution. This particle dispersion is centrifuged to remove the dispersion medium that is a supernatant, and then ultrapure water is added to the precipitate for ultrasonic dispersion. The steps of centrifugation, addition of ultrapure water to the precipitate, and ultrasonic dispersion are repeated several more times. As a result, an aqueous dispersion of aminocoumarin compound-encapsulating resin particles is obtained.
 前記樹脂合成用のモノマー原料とは、重合することにより、前記樹脂粒子を形成し得る原料である。 The monomer raw material for resin synthesis is a raw material capable of forming the resin particles by polymerization.
 アミノクマリン化合物の添加量は、樹脂合成用のモノマー原料1gに対し、通常1~50mgである。 The amount of aminocoumarin compound added is usually 1 to 50 mg with respect to 1 g of monomer raw material for resin synthesis.
 前記界面活性剤には特に制限はなく、通常の乳化重合反応に使用される界面活性剤を用いることができる。前記界面活性剤としては、アニオン系、ノニオン系およびカチオン系の全ての界面活性剤を用いることができる。アニオン系の界面活性剤としては、例えば、ドデシルベンゼンスルホン酸ナトリウム等が挙げられる。ノニオン系の界面活性剤としては、ポリエチレングリコール、ポリオキシエチレンアルキルエーテル等が挙げられる。カチオン系の界面活性剤としては、ドデシルトリメチルアンモニウムブロミド等が挙げられる。界面活性剤は、1種類単独で使用しても、2種類以上を併用してもよい。 The surfactant is not particularly limited, and a surfactant that is used in a usual emulsion polymerization reaction can be used. As the surfactant, all anionic, nonionic and cationic surfactants can be used. Examples of the anionic surfactant include sodium dodecylbenzenesulfonate. Examples of nonionic surfactants include polyethylene glycol and polyoxyethylene alkyl ether. Examples of the cationic surfactant include dodecyltrimethylammonium bromide. Surfactant may be used individually by 1 type, or may use 2 or more types together.
 市販の界面活性剤としては、例えば、「エマルゲン」(登録商標、花王(株)製)や「ネオペレックス」(登録商標、花王(株)製)を好適に用いることができる。エマルゲンの有効成分はポリオキシエチレンアルキルエーテルであり、ネオペレックスの有効成分はドデシルベンゼンスルホン酸ナトリウムである。 As commercially available surfactants, for example, “Emulgen” (registered trademark, manufactured by Kao Corporation) and “Neoperex” (registered trademark, manufactured by Kao Corporation) can be suitably used. The active ingredient of emulgen is polyoxyethylene alkyl ether, and the active ingredient of neoperex is sodium dodecylbenzenesulfonate.
 界面活性剤の添加量は、樹脂合成用のモノマー原料1gに対し、通常1~3mgである。 The addition amount of the surfactant is usually 1 to 3 mg per 1 g of the monomer raw material for resin synthesis.
 前記重合開始剤としては、熱によりラジカルを発生するアゾ化合物および過酸化物などの熱重合開始剤が挙げられ、アゾ化合物として好ましくはV-50(2,2‘-Azobis(2-methylpropionamidine)dihydrochloride)が挙げられ、過酸化物として好ましくは過硫酸アンモニウムが挙げられる。重合開始剤はレドックス重合開始剤であってもよい。 Examples of the polymerization initiator include thermal polymerization initiators such as azo compounds and peroxides that generate radicals by heat. V-50 (2,2′-Azobis (2-methylpropionamide) dihydrochloride is preferred as the azo compound. The peroxide is preferably ammonium persulfate. The polymerization initiator may be a redox polymerization initiator.
 重合開始剤の添加量は、樹脂合成用のモノマー原料1gに対し、通常0.1~1.5mg、好ましくは0.3~0.45mgである。 The addition amount of the polymerization initiator is usually 0.1 to 1.5 mg, preferably 0.3 to 0.45 mg per 1 g of the monomer raw material for resin synthesis.
 前記アミノクマリン化合物内包樹脂粒子において、前記樹脂粒子がアミノ樹脂粒子であることが好ましい。 In the aminocoumarin compound-encapsulating resin particles, the resin particles are preferably amino resin particles.
 前記アミノクマリン化合物内包樹脂粒子は、励起スペクトル極大波長が475~510nmであり、蛍光スペクトル極大波長が510~540nmであることが好ましい。 The aminocoumarin compound-containing resin particles preferably have an excitation spectrum maximum wavelength of 475 to 510 nm and a fluorescence spectrum maximum wavelength of 510 to 540 nm.
 式(1)で表わされるアミノクマリン化合物を樹脂に内包させて製造された本発明のアミノクマリン化合物内包樹脂粒子は、そのアミノクマリン化合物のスルホン基を水素原子で置換して形成されるアミノクマリン化合物を樹脂に内包させて製造されたアミノクマリン化合物内包樹脂粒子に比較して、発光強度が強い傾向がある。これは、式(1)で表わされるアミノクマリン化合物は、該アミノクマリン化合物のスルホン基を水素原子で置換して形成されるアミノクマリン化合物よりも、樹脂に内包されやすい性質があり、樹脂により多く取り込まれるからであると推測される。 The aminocoumarin compound-encapsulating resin particle of the present invention produced by encapsulating the aminocoumarin compound represented by the formula (1) in the resin is formed by substituting the sulfo group of the aminocoumarin compound with a hydrogen atom. Compared with the aminocoumarin compound-encapsulating resin particles produced by encapsulating in a resin, the emission intensity tends to be strong. This is because the aminocoumarin compound represented by the formula (1) is more easily included in the resin than the aminocoumarin compound formed by replacing the sulfone group of the aminocoumarin compound with a hydrogen atom. It is presumed that it is taken in.
[実施例1]
 20mLバイアル管瓶に下記式(3)で表わされる化合物 (3)600mgを入れ、発煙硫酸6mLを加えて、25℃にて4時間撹拌し、反応を行った。反応の進行はTLCにて確認した。具体的には、反応液の一部をNaOH水溶液にて中和した後、反応液にエタノールを加え、CHCl3 を2、MeOHを3の割合で混合した溶液を用いてTLCを行った。原料のRf値0.88に対し、目的物のRf値0.73であり、このTLCのデータより、反応の収束および目的物の生成を確認した。
[Example 1]
In a 20 mL vial tube, 600 mg of the compound (3) represented by the following formula (3) was added, 6 mL of fuming sulfuric acid was added, and the mixture was stirred at 25 ° C. for 4 hours to carry out the reaction. Progress of the reaction was confirmed by TLC. Specifically, a part of the reaction solution was neutralized with an aqueous NaOH solution, ethanol was added to the reaction solution, and TLC was performed using a solution in which CHCl 3 was mixed at a ratio of 2 and MeOH at a ratio of 3. The Rf value of the target product was 0.73 against the Rf value of 0.88 of the raw material, and the convergence of the reaction and the generation of the target product were confirmed from the TLC data.
 50mLバイアル管瓶に氷を8分目(30mL)まで入れ、この中に反応液を少しずつ加えた。生成した色素が懸濁した懸濁液が得られた。この懸濁液を遠心分離し、上澄み液を除去して色素を沈殿として回収した。沈殿を純水10mLで分散し、この分散液を遠心分離して、上澄み液を除去して、沈殿を回収し、再度、純水10mLで分散し、この分散液を遠心分離して上澄み液を除去して、沈殿を回収した。回収した沈殿をエタノールで分散し、この分散液を遠心分離し、上澄み液を除去して、沈殿として下記式(I)で表わされるアミノクマリン化合物Iを得た。アミノクマリン化合物Iの収率は80%であった。 Ice was put in a 50 mL vial tube until the 8th minute (30 mL), and the reaction solution was added little by little. A suspension in which the produced dye was suspended was obtained. The suspension was centrifuged, the supernatant was removed, and the dye was recovered as a precipitate. The precipitate is dispersed in 10 mL of pure water, the dispersion is centrifuged, the supernatant liquid is removed, the precipitate is recovered, dispersed again in 10 mL of pure water, and the dispersion is centrifuged to remove the supernatant. Removed and recovered the precipitate. The recovered precipitate was dispersed with ethanol, the dispersion was centrifuged, and the supernatant was removed to obtain an aminocoumarin compound I represented by the following formula (I) as a precipitate. The yield of aminocoumarin compound I was 80%.
 得られた沈殿物を乾燥後、得られた粉末を純水に加えた後、NaOH水溶液で中和し、沈殿を溶解し、溶液のpHを7~8とした。この溶液を凍結乾燥機にて乾燥する事により、アミノクマリン化合物IのNa塩を得た。アミノクマリン化合物Iは、スルホン酸体では水への溶解性が悪いのに対し、Na塩とする事で、水に速やかに溶解することを確認した。 After the obtained precipitate was dried, the obtained powder was added to pure water, then neutralized with an aqueous NaOH solution to dissolve the precipitate, and the pH of the solution was adjusted to 7-8. This solution was dried with a freeze dryer to obtain Na salt of aminocoumarin compound I. It was confirmed that the aminocoumarin compound I dissolves quickly in water by using Na salt, whereas the sulfonic acid form has poor solubility in water.
 アミノクマリン化合物Iを、再蒸留水(DDW)を10、エタノールを1の割合で混合して得られた溶媒に溶解して、10nM溶液を作製した。この溶液に対して、分光蛍光光度計F-7000(日立製作所(株)製)を用いて、励起スペクトル極大波長、蛍光スペクトル極大波長、および励起波長490nmでの蛍光強度を測定した。結果を表1に示す。励起スペクトルは検出する蛍光波長を固定して励起光の波長を走査して蛍光強度を測定した。蛍光スペクトルは励起光の波長を固定して蛍光強度を測定した。 The aminocoumarin compound I was dissolved in a solvent obtained by mixing double distilled water (DDW) 10 and ethanol at a ratio of 1 to prepare a 10 nM solution. The fluorescence intensity at the excitation spectrum maximum wavelength, the fluorescence spectrum maximum wavelength, and the excitation wavelength 490 nm was measured for this solution using a spectrofluorophotometer F-7000 (manufactured by Hitachi, Ltd.). The results are shown in Table 1. The excitation spectrum was measured by fixing the fluorescence wavelength to be detected and scanning the wavelength of the excitation light. In the fluorescence spectrum, the fluorescence intensity was measured with the wavelength of excitation light fixed.
 また、スルホン化前の原料および本化合物の1H-NMR測定を行ない、目的のスルホン化物が得られている事を確認した。
スルホン化前の1H-NMR(400MHz, CDCl3)(化合物(3)): δ= 1.31(s, 6H), 1.59(s, 6H), 1.77(t, 2H), 1.83(t, 2H), 3.29(t, 2H), 3.38(t, 2H), 7.30(s, 1H), 7.36(t, 1H), 7.47(t, 1H), 7.94(d, 1H), 8.00(d, 1H), 8.83(s, 1H)
スルホン化後の1H-NMR(400MHz, CD3OD)(アミノクマリン化合物I): δ= 1.37(s, 6H), 1.59(s, 6H), 1.83(s broad, 2H), 1.89(s broad, 2H), 3.52(s broad, 2H), 3.61(s broad, 2H), 7.46(s, 1H), 7.95(d, 1H), 8.11(d, 1H), 8.53(s, 1H), 8.69(s, 1H)
Further, 1H-NMR measurement of the raw material before sulfonation and the present compound was carried out to confirm that the desired sulfonated product was obtained.
1H-NMR before sulfonation (400 MHz, CDCl3) (compound (3)): δ = 1.31 (s, 6H), 1.59 (s, 6H), 1.77 (t, 2H), 1.83 (t, 2H), 3.29 (t, 2H), 3.38 (t, 2H), 7.30 (s, 1H), 7.36 (t, 1H), 7.47 (t, 1H), 7.94 (d, 1H), 8.00 (d, 1H), 8.83 ( s, 1H)
1H-NMR after sulfonation (400 MHz, CD3OD) (aminocoumarin compound I): δ = 1.37 (s, 6H), 1.59 (s, 6H), 1.83 (s broad, 2H), 1.89 (s broad, 2H) , 3.52 (s broad, 2H), 3.61 (s broad, 2H), 7.46 (s, 1H), 7.95 (d, 1H), 8.11 (d, 1H), 8.53 (s, 1H), 8.69 (s, 1H )
Figure JPOXMLDOC01-appb-C000005
Figure JPOXMLDOC01-appb-C000005
Figure JPOXMLDOC01-appb-C000006
[実施例2]
 式(3)で表わされる化合物の代わりに下記式(4)で表わされる化合物(4)を用いたこと以外は実施例1と同様の方法により、下記式(II)で表わされるアミノクマリン化合物IIを得た。アミノクマリン化合物IIの収率は82%であった。
Figure JPOXMLDOC01-appb-C000006
[Example 2]
An aminocoumarin compound II represented by the following formula (II) was prepared in the same manner as in Example 1 except that the compound (4) represented by the following formula (4) was used instead of the compound represented by the formula (3). Got. The yield of aminocoumarin compound II was 82%.
 アミノクマリン化合物IIを用いて、実施例1と同様に励起スペクトル極大波長、蛍光スペクトル極大波長、および蛍光強度を測定した。結果を表1に示す。
スルホン化前の1H-NMR(400MHz, CDCl3)(化合物(4)): δ= 1.99(m, 4H), 2.79(t, 2H), 2.94(t, 2H), 3.33(s broad, 4H), 7.05(s, 1H), 7.34(t, 1H), 7.46(t, 1H), 7.92(d, 1H), 8.00(d, 1H), 8.80(s, 1H)
スルホン化後の1H-NMR(400MHz, CD3OD)(アミノクマリン化合物II): δ= 1.95(m, 4H), 2.78(t, 2H), 2.84(t, 2H), 3.36(m, 4H), 7.20(s, 1H), 7.89(d, 1H), 7.94(d, 1H), 8.38(s, 1H), 8.80(s, 1H)
Using the aminocoumarin compound II, the excitation spectrum maximum wavelength, the fluorescence spectrum maximum wavelength, and the fluorescence intensity were measured in the same manner as in Example 1. The results are shown in Table 1.
1H-NMR before sulfonation (400 MHz, CDCl3) (compound (4)): δ = 1.99 (m, 4H), 2.79 (t, 2H), 2.94 (t, 2H), 3.33 (s broad, 4H), 7.05 (s, 1H), 7.34 (t, 1H), 7.46 (t, 1H), 7.92 (d, 1H), 8.00 (d, 1H), 8.80 (s, 1H)
1H-NMR after sulfonation (400 MHz, CD3OD) (aminocoumarin compound II): δ = 1.95 (m, 4H), 2.78 (t, 2H), 2.84 (t, 2H), 3.36 (m, 4H), 7.20 (s, 1H), 7.89 (d, 1H), 7.94 (d, 1H), 8.38 (s, 1H), 8.80 (s, 1H)
Figure JPOXMLDOC01-appb-C000007
Figure JPOXMLDOC01-appb-C000007
Figure JPOXMLDOC01-appb-C000008
[実施例3]
 式(3)で表わされる化合物の代わりに下記式(5)で表わされる化合物(5)を用いたこと以外は実施例1と同様の方法により、下記式(III)で表わされるアミノクマリン化合物IIIを得た。アミノクマリン化合物IIIの収率は80%であった。
Figure JPOXMLDOC01-appb-C000008
[Example 3]
The aminocoumarin compound III represented by the following formula (III) was prepared in the same manner as in Example 1 except that the compound (5) represented by the following formula (5) was used instead of the compound represented by the formula (3). Got. The yield of aminocoumarin compound III was 80%.
 アミノクマリン化合物IIIを用いて、実施例1と同様に励起スペクトル極大波長および蛍光スペクトル極大波長を測定した。結果を表1に示す。 Excitation spectrum maximum wavelength and fluorescence spectrum maximum wavelength were measured in the same manner as in Example 1 using aminocoumarin compound III. The results are shown in Table 1.
Figure JPOXMLDOC01-appb-C000009
Figure JPOXMLDOC01-appb-C000009
Figure JPOXMLDOC01-appb-C000010
[実施例4]
 式(3)で表わされる化合物の代わりに下記式(6)で表わされる化合物(6)を用いたこと以外は実施例1と同様の方法により、下記式(IV)で表わされるアミノクマリン化合物IVを得た。アミノクマリン化合物IVの収率は75%であった。
Figure JPOXMLDOC01-appb-C000010
[Example 4]
The aminocoumarin compound IV represented by the following formula (IV) was prepared in the same manner as in Example 1 except that the compound (6) represented by the following formula (6) was used instead of the compound represented by the formula (3). Got. The yield of aminocoumarin compound IV was 75%.
 アミノクマリン化合物IVを用いて、実施例1と同様に励起スペクトル極大波長および蛍光スペクトル極大波長を測定した。結果を表1に示す。
スルホン化前の1H-NMR(400MHz, CDCl3)(化合物(6)): δ= 1.98(m, 4H), 2.78(t, 2H), 2.93(t, 2H), 3.33(m, 4H), 6.98(s, 1H), 7.30(d, 1H), 7.31(d, 1H), 7.57(t, 1H), 7.78(t, 1H), 8.50(s, 1H)
スルホン化後の1H-NMR(400MHz, CD3OD)(アミノクマリン化合物IV): δ= 1.97(s broad, 4H), 2.80(m, 2H), 2.87(m, 2H), 3.39(m, 4H), 7.19(s, 1H), 7.72(d, 1H), 7.87(d, 1H), 8.05(s, 1H), 8.65(s, 1H)
Excitation spectrum maximum wavelength and fluorescence spectrum maximum wavelength were measured in the same manner as Example 1 using aminocoumarin compound IV. The results are shown in Table 1.
1H-NMR before sulfonation (400 MHz, CDCl3) (compound (6)): δ = 1.98 (m, 4H), 2.78 (t, 2H), 2.93 (t, 2H), 3.33 (m, 4H), 6.98 (s, 1H), 7.30 (d, 1H), 7.31 (d, 1H), 7.57 (t, 1H), 7.78 (t, 1H), 8.50 (s, 1H)
1H-NMR after sulfonation (400 MHz, CD3OD) (aminocoumarin compound IV): δ = 1.97 (s broad, 4H), 2.80 (m, 2H), 2.87 (m, 2H), 3.39 (m, 4H), 7.19 (s, 1H), 7.72 (d, 1H), 7.87 (d, 1H), 8.05 (s, 1H), 8.65 (s, 1H)
Figure JPOXMLDOC01-appb-C000011
Figure JPOXMLDOC01-appb-C000011
Figure JPOXMLDOC01-appb-C000012
[実施例5]
 式(3)で表わされる化合物の代わりに下記式(7)で表わされる化合物(7)を用いたこと以外は実施例1と同様の方法により、下記式(V)で表わされるアミノクマリン化合物Vを得た。アミノクマリン化合物Vの収率は70%であった。
Figure JPOXMLDOC01-appb-C000012
[Example 5]
The aminocoumarin compound V represented by the following formula (V) was prepared in the same manner as in Example 1 except that the compound (7) represented by the following formula (7) was used instead of the compound represented by the formula (3). Got. The yield of aminocoumarin compound V was 70%.
 アミノクマリン化合物Vを用いて、実施例1と同様に励起スペクトル極大波長および蛍光スペクトル極大波長を測定した。結果を表1に示す。
スルホン化前の1H-NMR(400MHz, CDCl3)(化合物(7)): δ= 1.98(m, 4H), 2.78(t, 2H), 2.93(t, 2H), 3.33(m, 4H), 6.98(s, 1H), 7.30(d, 1H), 7.31(d, 1H), 7.57(t, 1H), 7.78(t, 1H), 8.50(s, 1H)
スルホン化後の1H-NMR(400MHz, CD3SOCD3)(アミノクマリン化合物V): δ= 1.97(s broad, 4H), 2.80(m, 2H), 2.87(m, 2H), 3.39(m, 4H), 7.19(s, 1H), 7.72(d, 1H), 7.87(d, 1H), 8.05(s, 1H), 8.65(s, 1H)
Using the aminocoumarin compound V, the excitation spectrum maximum wavelength and the fluorescence spectrum maximum wavelength were measured in the same manner as in Example 1. The results are shown in Table 1.
1H-NMR before sulfonation (400 MHz, CDCl 3) (compound (7)): δ = 1.98 (m, 4H), 2.78 (t, 2H), 2.93 (t, 2H), 3.33 (m, 4H), 6.98 (s, 1H), 7.30 (d, 1H), 7.31 (d, 1H), 7.57 (t, 1H), 7.78 (t, 1H), 8.50 (s, 1H)
1H-NMR after sulfonation (400 MHz, CD3SOCD3) (aminocoumarin compound V): δ = 1.97 (s broad, 4H), 2.80 (m, 2H), 2.87 (m, 2H), 3.39 (m, 4H), 7.19 (s, 1H), 7.72 (d, 1H), 7.87 (d, 1H), 8.05 (s, 1H), 8.65 (s, 1H)
Figure JPOXMLDOC01-appb-C000013
Figure JPOXMLDOC01-appb-C000013
Figure JPOXMLDOC01-appb-C000014
[実施例6]
 式(3)で表わされる化合物の代わりに下記式(8)で表わされる化合物(8)を用いたこと以外は実施例1と同様の方法により、下記式(VI)で表わされるアミノクマリン化合物VIを得た。アミノクマリン化合物VIの収率は75%であった。
Figure JPOXMLDOC01-appb-C000014
[Example 6]
The aminocoumarin compound VI represented by the following formula (VI) was prepared in the same manner as in Example 1 except that the compound (8) represented by the following formula (8) was used instead of the compound represented by the formula (3). Got. The yield of aminocoumarin compound VI was 75%.
 アミノクマリン化合物VIを用いて、実施例1と同様に励起スペクトル極大波長および蛍光スペクトル極大波長を測定した。結果を表1に示す。 Excitation spectrum maximum wavelength and fluorescence spectrum maximum wavelength were measured in the same manner as in Example 1 using aminocoumarin compound VI. The results are shown in Table 1.
Figure JPOXMLDOC01-appb-C000015
Figure JPOXMLDOC01-appb-C000015
Figure JPOXMLDOC01-appb-C000016
[比較例1]
 アミノクマリン化合物Iの代わりに下記式(i)で表わされるアミノクマリン化合物iを用いたこと以外は実施例1と同様に、蛍光強度を測定した。結果を表1に示す。
Figure JPOXMLDOC01-appb-C000016
[Comparative Example 1]
The fluorescence intensity was measured in the same manner as in Example 1 except that aminocoumarin compound i represented by the following formula (i) was used instead of aminocoumarin compound I. The results are shown in Table 1.
Figure JPOXMLDOC01-appb-C000017
[比較例2]
 式(3)で表わされる化合物の代わりに上記式(i)で表わされるアミノクマリン化合物(i)を用いたこと以外は実施例1と同様の方法により、下記式(ii)で表わされるアミノクマリン化合物iiを得た。
Figure JPOXMLDOC01-appb-C000017
[Comparative Example 2]
The aminocoumarin represented by the following formula (ii) was prepared in the same manner as in Example 1 except that the aminocoumarin compound (i) represented by the above formula (i) was used instead of the compound represented by the formula (3). Compound ii was obtained.
 アミノクマリン化合物iiを用いて、実施例1と同様に励起スペクトル極大波長、蛍光スペクトル極大波長、および蛍光強度を測定した。結果を表1に示す。
スルホン化前の1H-NMR(400MHz, CDCl3)(アミノクマリン化合物(i)): δ= 1.25(t, 6H), 3.46(q, 4H), 6.56(s, 1H), 6.67(d, 1H), 7.36(t,1H), 7.48(m, 2H), 7.99(d, 1H), 8.01(d, 1H), 8.90(s, 1H)
スルホン化後の1H-NMR(400MHz, CD3SOCD3)(アミノクマリン化合物ii): δ= 1.67(t, 6H), 3.51(m, 4H), 6.68(s, 1H), 6.86(d, 1H), 7.41(d, 1H), 7.78(d, 1H), 7.91(d, 1H), 8.30(s, 1H), 9.03(s, 1H)
Using the aminocoumarin compound ii, the excitation spectrum maximum wavelength, the fluorescence spectrum maximum wavelength, and the fluorescence intensity were measured in the same manner as in Example 1. The results are shown in Table 1.
1H-NMR before sulfonation (400 MHz, CDCl3) (aminocoumarin compound (i)): δ = 1.25 (t, 6H), 3.46 (q, 4H), 6.56 (s, 1H), 6.67 (d, 1H) , 7.36 (t, 1H), 7.48 (m, 2H), 7.99 (d, 1H), 8.01 (d, 1H), 8.90 (s, 1H)
1H-NMR after sulfonation (400 MHz, CD3SOCD3) (aminocoumarin compound ii): δ = 1.67 (t, 6H), 3.51 (m, 4H), 6.68 (s, 1H), 6.86 (d, 1H), 7.41 (d, 1H), 7.78 (d, 1H), 7.91 (d, 1H), 8.30 (s, 1H), 9.03 (s, 1H)
Figure JPOXMLDOC01-appb-C000018
[比較例3]
 式(3)で表わされる化合物の代わりに下記式(9)で表わされる化合物(9)を用いたこと以外は実施例1と同様の方法により、下記式(iii)で表わされるアミノクマリン化合物iiiを得た。
Figure JPOXMLDOC01-appb-C000018
[Comparative Example 3]
Aminocoumarin compound iii represented by the following formula (iii) in the same manner as in Example 1 except that the compound (9) represented by the following formula (9) was used instead of the compound represented by the formula (3). Got.
 アミノクマリン化合物iiiを用いて、実施例1と同様に励起スペクトル極大波長および蛍光スペクトル極大波長を測定した。結果を表1に示す。 Using the aminocoumarin compound iii, the excitation spectrum maximum wavelength and the fluorescence spectrum maximum wavelength were measured in the same manner as in Example 1. The results are shown in Table 1.
Figure JPOXMLDOC01-appb-C000019
Figure JPOXMLDOC01-appb-C000019
Figure JPOXMLDOC01-appb-C000020
[比較例4]
 式(3)で表わされる化合物の代わりに下記式(10)で表わされる化合物(10)を用いたこと以外は実施例1と同様の方法により、下記式(iv)で表わされるアミノクマリン化合物ivを得た。
Figure JPOXMLDOC01-appb-C000020
[Comparative Example 4]
The aminocoumarin compound iv represented by the following formula (iv) was prepared in the same manner as in Example 1 except that the compound (10) represented by the following formula (10) was used instead of the compound represented by the formula (3). Got.
 アミノクマリン化合物ivを用いて、実施例1と同様に励起スペクトル極大波長および蛍光スペクトル極大波長を測定した。結果を表1に示す。 Using the aminocoumarin compound iv, the excitation spectrum maximum wavelength and the fluorescence spectrum maximum wavelength were measured in the same manner as in Example 1. The results are shown in Table 1.
Figure JPOXMLDOC01-appb-C000021
Figure JPOXMLDOC01-appb-C000021
Figure JPOXMLDOC01-appb-C000022
Figure JPOXMLDOC01-appb-C000022
Figure JPOXMLDOC01-appb-T000023
[実施例7]
 アミノクマリン化合物I 14.4mgを水22mLに加えて溶解させた。この溶液に乳化重合用乳化剤のエマルジョン(登録商標)430(ポリオキシエチレンオレイルエーテル、花王社製)の5%水溶液を2mL加えた。
Figure JPOXMLDOC01-appb-T000023
[Example 7]
14.4 mg of aminocoumarin compound I was added to 22 mL of water and dissolved. To this solution, 2 mL of a 5% aqueous solution of an emulsion (registered trademark) 430 (polyoxyethylene oleyl ether, manufactured by Kao Corporation) of an emulsifier for emulsion polymerization was added.
 この溶液をホットスターラー上で撹拌しながら70℃まで昇温させた後、この溶液にメラミン樹脂原料ニカラックMX-035(日本カーバイド工業社製)を0.65g加えた。この溶液に反応開始剤としてドデシルベンゼンスルホン酸(関東化学社製)の10%水溶液を1000μL加え、70℃で50分間加熱撹拌し、その後、90℃に昇温して20分間加熱撹拌した。以上の操作により、アミノクマリン化合物内包樹脂粒子Iを得た。 The solution was heated to 70 ° C. while stirring on a hot stirrer, and then 0.65 g of melamine resin raw material Nicalak MX-035 (manufactured by Nippon Carbide Industries Co., Ltd.) was added to the solution. To this solution was added 1000 μL of a 10% aqueous solution of dodecylbenzenesulfonic acid (manufactured by Kanto Chemical Co., Ltd.) as a reaction initiator, and the mixture was heated and stirred at 70 ° C. for 50 minutes, then heated to 90 ° C. and stirred for 20 minutes. By the above operation, aminocoumarin compound-encapsulating resin particles I were obtained.
 得られたアミノクマリン化合物内包樹脂粒子Iの分散液から、純水による洗浄を行い、余剰の樹脂原料やアミノクマリン化合物などの不純物を除いた。具体的には、遠心分離機(クボタ社製マイクロ冷却遠心機3740)にて20000Gで15分間、遠心分離し、上澄み除去後、超純水を加えて超音波照射して再分散した。遠心分離、上澄み除去および超純水への再分散による洗浄を5回繰り返した。 The resulting dispersion of aminocoumarin compound-encapsulating resin particles I was washed with pure water to remove excess resin raw materials and impurities such as aminocoumarin compounds. Specifically, the mixture was centrifuged at 20000 G for 15 minutes in a centrifuge (Kubota Micro Cooling Centrifuge 3740), and after removing the supernatant, ultrapure water was added and ultrasonically irradiated to redisperse. Centrifugation, supernatant removal, and washing by redispersion in ultrapure water were repeated 5 times.
 アミノクマリン化合物内包樹脂粒子Iの平均粒径をSEM画像の粒子直径より算出した。結果を表2に示す。 The average particle size of the aminocoumarin compound-encapsulating resin particles I was calculated from the particle diameter of the SEM image. The results are shown in Table 2.
 アミノクマリン化合物内包樹脂粒子Iを0.0189mg/mLに希釈して100uLを取り、蛍光用ミクロセルに入れて、分光蛍光光度計F-7000(日立製作所(株)製)を用いて、励起波長490nmで蛍光強度を測定した。結果を表2に示す。 Aminocoumarin compound-encapsulating resin particle I is diluted to 0.0189 mg / mL, 100 uL is taken, put into a fluorescence microcell, and using a spectrofluorometer F-7000 (manufactured by Hitachi, Ltd.) at an excitation wavelength of 490 nm. The fluorescence intensity was measured. The results are shown in Table 2.
 アミノクマリン化合物内包樹脂粒子Iを、下記のFACS(Fluorescence Activated Cell Sorting)およびFISH(Fluorescence in situ hybridization )に供した。
(FACS評価)
 アミノクマリン化合物内包樹脂粒子Iの末端にNHS-PEG(polyethylene glycol)-マレイミド試薬を用いてマレイミドを導入し、これにチオール化した抗HER2抗体を結合させた。
The aminocoumarin compound-encapsulating resin particles I were subjected to the following FACS (Fluorescence Activated Cell Sorting) and FISH (Fluorescence in situ hybridization).
(FACS evaluation)
Maleimide was introduced into the end of the aminocoumarin compound-encapsulating resin particle I using NHS-PEG (polyethylene glycol) -maleimide reagent, and a thiolated anti-HER2 antibody was bound thereto.
 ATCC(American Type Culture Collection)から入手したCOLO201の凍結細胞を37℃の恒温槽で融かし、1×105個/mL程度の細胞を培地に懸濁して、25cm2フラスコで最初の培養を実施した。1×106個/mL程度に細胞が増えた培養液をトリプシン処理し、フラスコからはがした細胞の一部をCellバンカー液(10%DMSO)で希釈し、凍結乾燥して、保存細胞とした。残りの細胞は継代して目的量5×107個程度まで培養し、スクレーパーで浮かして回収後、一部をFACS測定に使用した。 The frozen cells of COLO201 obtained from ATCC (American Type Culture Collection) are thawed in a 37 ° C constant temperature bath, and about 1 × 10 5 cells / mL are suspended in the medium, and the first culture is performed in a 25 cm 2 flask. Carried out. Trypsinize the culture medium with about 1 × 10 6 cells / mL and dilute a part of the cells detached from the flask with Cell bunker solution (10% DMSO). did. The remaining cells were subcultured and cultured to a target amount of about 5 × 10 7 cells. After floating and recovering with a scraper, a part was used for FACS measurement.
 培養細胞表面に存在するHER2タンパク質を、FACSCalibur(商品名;ベクトン・ディッキンソン社製)で計測した。アミノクマリン化合物内包樹脂粒子IのPBS溶液と上述のように培養したCOLO201との混合液を4℃ で、30分間インキュベイトし、その100μlを測定用チューブに採り、Assay Diluent(商品名、ベクトン・デッキンソン社製)で2mlに希釈して、FACSCaliburにインジェクトした。 HER2 protein present on the surface of cultured cells was measured with FACSCalibur (trade name; manufactured by Becton Dickinson). A mixture of the PBS solution of aminocoumarin compound-encapsulating resin particles I and COLO201 cultured as described above was incubated at 4 ° C. for 30 minutes, 100 μl of the mixture was taken into a measuring tube, and Assay Diluent (trade name, Becton It was diluted to 2 ml with Deckson Corporation and injected into FACSCalibur.
 結果を表2に示す。表2中にFACSの結果として示された図は、490nm励起光による530nmの蛍光強度を横軸に、カウント数を縦軸にしたヒストグラムである。この図においては、ヒストグラムが右側にシフトしているほど蛍光強度が強い、つまり明るいことを示す。この図では、実施例7の結果は、下記のアミノクマリン化合物内包樹脂粒子iを用いた比較例5の結果と比較して示されている。他の実施例および比較例6~8についても同様である。蛍光強度90付近にピークを有するヒストグラムが比較例5のヒストグラムであり、蛍光強度500付近にピークを有するヒストグラムが実施例7のヒストグラムである。実施例7のヒストグラムは、比較例5のヒストグラムからかなり右側にシフトしていることがわかる。この結果から、実施例7のアミノクマリン化合物内包樹脂粒子Iは、比較例5のアミノクマリン化合物内包樹脂粒子iより、蛍光強度が強く、明るいことがわかる。
(FISH評価)
 〔BACプローブの調製〕
 CellBiochemBiophys.2006;45(1)59の記載の方法に従って、以下のように核酸分子を調製した。GSP社から購入したHER2-DNAクローン(約150kbp)1μg(5μL)に対して、ニックトランスレーション用のキット(製品名「GSP-ニックトランスレーションキット」K-015、GSP社製)のプロトコールに従い、以下のようにニックトランスレーション法により、HER2のDNAクローン(核酸分子)のdTTPをDNP標識dUTPで置換した。
The results are shown in Table 2. The diagram shown as a result of FACS in Table 2 is a histogram with the horizontal axis representing the fluorescence intensity of 530 nm by 490 nm excitation light and the vertical axis representing the count number. In this figure, the fluorescence intensity is stronger, that is, brighter as the histogram is shifted to the right side. In this figure, the result of Example 7 is shown in comparison with the result of Comparative Example 5 using the following aminocoumarin compound-encapsulating resin particles i. The same applies to other examples and comparative examples 6 to 8. A histogram having a peak near the fluorescence intensity 90 is the histogram of Comparative Example 5, and a histogram having a peak near the fluorescence intensity 500 is the histogram of Example 7. It can be seen that the histogram of Example 7 is considerably shifted to the right from the histogram of Comparative Example 5. From this result, it can be seen that the aminocoumarin compound-encapsulating resin particles I of Example 7 have a stronger fluorescence intensity and brighter than the aminocoumarin compound-encapsulating resin particles i of Comparative Example 5.
(FISH evaluation)
[Preparation of BAC probe]
CellBiochemBiophys. In accordance with the method described in 2006; 45 (1) 59, a nucleic acid molecule was prepared as follows. For 1 μg (5 μL) of the HER2-DNA clone (about 150 kbp) purchased from GSP, according to the protocol of the kit for nick translation (product name “GSP-Nick Translation Kit” K-015, manufactured by GSP) As described below, dTTP of the HER2 DNA clone (nucleic acid molecule) was replaced with DNP-labeled dUTP by the nick translation method.
 〔ニックトランスレーションによる標準的なビオチン標識方法〕
 まず、下記の試薬を遠心チューブ内で混合した。
・10×NickBuffer(Tris-HCl[pH7.2]、MgSO4、DTT)・・・2.5μL
・BSA(Nuclease-free BSA)・・・1.5μL
・dNTP mix(dATP、dCTP、dCTP)・・・5μL
・dTTP・・・0.5μL、
・DNP-11-dUTP(製品番号NEL551001EA、PerkinElmer社製、250nmol/25μL)・・・0.15μL
・純水(Nuclease free water)・・・3μL
・上記HER2-DNAクローン約150kbp 1μgの水溶液・・・5μL
・DNA PоlymeraseI(Tris-HCl[pH7.5]、EDTA、DTT、glycerоl)・・・1μL
・DNaseI・・・5μL
 次に、15℃で4時間反応させ、70℃で10分間加熱して反応を停止させた。反応後の遠心チューブに25μLの蒸留水を添加した。ビオチン標識済みのBACプローブの反応溶液を核酸精製用マイクロスピンカラム(GEヘルスケア社製「MicroSpin S-200HR Column」、製品番号「#27-5120-01」)により精製した。
[Standard biotin labeling method by nick translation]
First, the following reagents were mixed in a centrifuge tube.
・ 10 × NickBuffer (Tris-HCl [pH 7.2], MgSO 4 , DTT): 2.5 μL
・ BSA (Nuclease-free BSA) ・ ・ ・ 1.5μL
DNTP mix (dATP, dCTP, dCTP): 5 μL
・ DTTP ... 0.5μL,
・ DNP-11-dUTP (Product No. NEL551001EA, PerkinElmer, 250 nmol / 25 μL) ... 0.15 μL
・ Pure water (Nuclease free water) ・ ・ ・ 3μL
・ Aqueous solution of about 150 kbp 1 μg of the HER2-DNA clone 5 μL
DNA Polymerase I (Tris-HCl [pH 7.5], EDTA, DTT, glyceryl) ... 1 μL
・ DNaseI ... 5μL
Next, the reaction was performed at 15 ° C. for 4 hours, and the reaction was stopped by heating at 70 ° C. for 10 minutes. 25 μL of distilled water was added to the centrifuge tube after the reaction. The biotin-labeled BAC probe reaction solution was purified by a microspin column for nucleic acid purification (“MicroSpin S-200HR Column” manufactured by GE Healthcare, product number “# 27-5120-01”).
 この溶液に対して、3M酢酸ナトリウム溶液(pH5.2)を約5.56μL、100%エタノールを150μL添加し、-20℃で1時間以上静置した。4℃で16000rpm10分間遠心して沈殿を形成した。さらに、70%エタノールを500μL添加して、4℃、16000rpmで1分間遠心し上澄みを除去した。沈殿物に5~10μLの蒸留水を添加して完全に溶解させ、最終濃度1μg/250μLのDNP標識されたBACプローブの溶液を得た。 To this solution, about 5.56 μL of 3M sodium acetate solution (pH 5.2) and 150 μL of 100% ethanol were added, and left at −20 ° C. for 1 hour or longer. A precipitate was formed by centrifugation at 16000 rpm for 10 minutes at 4 ° C. Furthermore, 500 μL of 70% ethanol was added and centrifuged at 16000 rpm for 1 minute at 4 ° C. to remove the supernatant. The precipitate was completely dissolved by adding 5 to 10 μL of distilled water to obtain a DNP-labeled BAC probe solution having a final concentration of 1 μg / 250 μL.
 〔アミノクマリン化合物内包樹脂粒子と上記BACプローブとが結合したDNAプローブの調製〕
 アミノクマリン化合物内包樹脂粒子Iの表面アミノ基にNHS-PEG(polyethylene glycol)-マレイミド試薬を反応してマレイミドを導入し、これに抗DNP抗体を結合させた。
[Preparation of DNA probe in which aminocoumarin compound-encapsulating resin particles and BAC probe are bound]
NHS-PEG (polyethylene glycol) -maleimide reagent was reacted with the surface amino group of the aminocoumarin compound-encapsulating resin particle I to introduce maleimide, and an anti-DNP antibody was bound thereto.
 上記ニックトランスレーションによりDNP標識したBACプローブを25μL(濃度1μg/250μL)および抗DNP抗体で表面修飾されたアミノクマリン化合物内包樹脂粒子を1.0μL(50nmol/50μL)含む溶液を混合して、室温で30分間結合反応を行い、HER-2検出用のDNAプローブ試薬を得た。 A solution containing 25 μL (concentration 1 μg / 250 μL) of a DNP-labeled BAC probe by nick translation and 1.0 μL (50 nmol / 50 μL) of aminocoumarin compound-encapsulating resin particles surface-modified with an anti-DNP antibody was mixed to room temperature. Then, a binding reaction was performed for 30 minutes to obtain a DNA probe reagent for HER-2 detection.
 〔DNAプローブの保存〕
 上述のように得られたDNAプローブをハイブリダイゼーション緩衝液(25%脱イオン化したホルムアミド、2×SSC、200ng/μLサケ精子DNA、5×デンハルト溶液、50mMのリン酸ナトリウム、pH7.0、1mMEDTA)に終濃度1~5ng/μLとなるように希釈した。必要に応じて、S300サイズのスピンカラム(Amersham Biosciences,Piscataway,NJ)により遊離のリガンドを除去した。直ぐに使用しない場合、DNAプローブを-20℃で冷凍保存した。
[Storage of DNA probes]
Hybridization buffer (25% deionized formamide, 2 × SSC, 200 ng / μL salmon sperm DNA, 5 × Denhardt's solution, 50 mM sodium phosphate, pH 7.0, 1 mM EDTA) Diluted to a final concentration of 1-5 ng / μL. If necessary, free ligand was removed with an S300 size spin column (Amersham Biosciences, Piscataway, NJ). If not used immediately, the DNA probe was stored frozen at -20 ° C.
 〔HER2遺伝子のコピー数を測定〕
 FISHによりHER2遺伝子のコピー数を測定した。FISHは以下に示すように、脱パラフィン処理、検体スライドの前処理、酵素処理、検体の固定処理、プローブの準備、検体スライドのDNAの変性処理、ハイブリダイゼーション処理、スライドグラスの洗浄処理、およびDAPI染色処理をこの順で行うことで実施した。
[Measure HER2 gene copy number]
The copy number of the HER2 gene was measured by FISH. As shown below, FISH includes deparaffinization, specimen slide pretreatment, enzyme treatment, specimen fixing treatment, probe preparation, specimen slide DNA denaturation treatment, hybridization treatment, slide glass washing treatment, and DAPI. The staining process was performed in this order.
 〔脱パラフィン処理〕
 HER2陽性染色対照標本の検体スライド(パソロジー研究所社製「HER2-FISHコントロールスライド Code PS-09006」)を、以下の(1)~(4)の順で処理することで脱パラフィン処理を行った。(1)ヘモディー(Hemo-De)に常温で10分間浸漬する。(2)検体スライドを新しいHemo-Deに常温10分間浸漬する。同じ操作を3回繰り返す。(3)検体スライドを100%エタノールで常温で5分間浸漬し、2回洗浄し、脱水処理を行う。(4)検体スライドを風乾または45~50℃のスライドウォーマー上で乾燥させる。
[Deparaffinization]
Deparaffinization was performed by treating a specimen slide of a HER2-positive stained control specimen (“HER2-FISH Control Slide Code PS-09006” manufactured by Pathology Laboratories) in the order of (1) to (4) below. . (1) Immerse in Hemo-De for 10 minutes at room temperature. (2) Immerse the specimen slide in new Hemo-De for 10 minutes at room temperature. Repeat the same operation three times. (3) The specimen slide is immersed in 100% ethanol at room temperature for 5 minutes, washed twice, and dehydrated. (4) The specimen slide is air-dried or dried on a slide warmer at 45 to 50 ° C.
 〔検体スライドの前処理〕
 DNAプローブの到達性を向上させるために、上記検体スライドに対し以下の(1)~(6)の順で前処理を行い、細胞膜及び核膜の蛋白質の除去を行った。(1)検体スライドを0.2mоl/L HClで室温、20分間処理する。(2)検体スライドを精製水に3分間浸漬する。(3)検体スライドを洗浄緩衝液(2xSSC:standard sailine citrate)に3分間浸漬する。(4)検体スライドを80℃の前処理溶液(1N NaSCN)に30分間浸漬する。(5)検体スライドを精製水に1分間浸漬する。(6)検体スライドを洗浄緩衝液(2xSSC)に5分間浸漬し、この浸漬操作を2回繰り返す。
[Pretreatment of specimen slide]
In order to improve the reachability of the DNA probe, the specimen slide was pretreated in the following order (1) to (6) to remove proteins from the cell membrane and the nuclear membrane. (1) Treat the specimen slide with 0.2 mol / L HCl at room temperature for 20 minutes. (2) Immerse the specimen slide in purified water for 3 minutes. (3) The specimen slide is immersed in a washing buffer solution (2 × SSC: standard saline citrate) for 3 minutes. (4) The specimen slide is immersed in a pretreatment solution (1N NaSCN) at 80 ° C. for 30 minutes. (5) Immerse the specimen slide in purified water for 1 minute. (6) The specimen slide is immersed in a washing buffer solution (2 × SSC) for 5 minutes, and this immersion operation is repeated twice.
 〔酵素処理〕
 前処理を行った検体スライドに対して、以下の(1)~(4)の処理をこの順で行うことで酵素処理を行った。(1)前処理した検体スライドを取り出し、ペーパータオルにスライドグラスの下端をつけて余分な洗浄緩衝液を取り除く。(2)検体スライドを37℃に加温したプロテアーゼ溶液に10~60分間浸漬する。この浸漬処理は、細胞膜及び核膜のタンパク質、特にコラーゲンの分解をするために、25mg プロテアーゼ(2500-3000Units/mg)[ペプシン]/1M NaCl[pH2.0]50mLで37℃、60分間)で処理することが望ましい。(3)検体スライドを洗浄緩衝液に5分間浸漬する。この操作を2回繰り返す。(4)検体スライドを風乾または45~50℃のスライドウォーマー上で2~5分間乾燥させる。
[Enzyme treatment]
The sample treatment that had been pretreated was subjected to enzyme treatment by performing the following treatments (1) to (4) in this order. (1) Take out the pretreated specimen slide, attach the lower end of the slide glass to a paper towel, and remove excess washing buffer. (2) The specimen slide is immersed in a protease solution heated to 37 ° C. for 10 to 60 minutes. This immersion treatment is performed with 25 mg protease (2500-3000 Units / mg) [pepsin] / 1M NaCl [pH 2.0] in 50 mL at 37 ° C. for 60 minutes) in order to decompose cell membrane and nuclear membrane proteins, particularly collagen. It is desirable to process. (3) Immerse the specimen slide in the washing buffer for 5 minutes. This operation is repeated twice. (4) The specimen slide is air-dried or dried on a slide warmer at 45 to 50 ° C. for 2 to 5 minutes.
 〔検体の固定〕
 検体の固定処理として、前処理を行った検体スライドに対して以下の(1)~(3)の処理を行った。(1)検体スライドを10%中性緩衝ホルマリン(和光純薬社製「4%パラホルムアルデヒド・リン酸緩衝液」、製品番号163-20145)に常温で10分間浸漬する。(2)検体スライドを洗浄緩衝液に5分間浸漬する。これと同じ操作を2回繰り返す。(3)検体スライドを風乾または45~50℃のスライドウォーマー上で2~5分間乾燥させる。
[Specimen fixation]
As the specimen fixing process, the following processes (1) to (3) were performed on the specimen slide that had been pretreated. (1) The specimen slide is immersed in 10% neutral buffered formalin (“4% paraformaldehyde / phosphate buffer” manufactured by Wako Pure Chemical Industries, Ltd., product number 163-1004) at room temperature for 10 minutes. (2) Immerse the specimen slide in the washing buffer for 5 minutes. Repeat the same operation twice. (3) The specimen slide is air-dried or dried on a slide warmer at 45 to 50 ° C. for 2 to 5 minutes.
 〔プローブの準備〕
 冷凍保存しておいたDNAプローブ試薬の溶液を室温に戻し、正確な容量を採液可能なピペッティング操作ができる程度まで溶液の粘度を十分にさげて、ボルテックスミキサー等で溶液を混和した。
[Preparation of probe]
The solution of the DNA probe reagent that had been stored in a frozen state was returned to room temperature, the viscosity of the solution was sufficiently reduced to such an extent that a pipetting operation capable of collecting an accurate volume was possible, and the solution was mixed with a vortex mixer or the like.
 〔検体スライドのDNAの変性〕
 検体スライド上のDNAの変性処理として、検体の固定処理を行った検体スライドに対して以下の(1)~(8)の処理を行った。(1)検体スライドの作成前に水で湿らせたペーパータオルを底に敷いた湿潤箱(気密性の容器であり、その側面をペーパータオルでテーピングしたもの)を37℃インキュベータ内に載置して予備加熱する。(2)変性溶液(70% ホルムアミド/SSC[150mM NaCl、15mMクエン酸ナトリウム])のpHが常温でpH7.0~8.0であることを確かめる。変性溶液をコプリンジャーに入れ、溶液が72℃±1℃になるまで温浴槽で加温する(72±1℃の温浴槽に少なくとも30分間置く)。(3)ハイブリダイゼーション領域がどの部分か分かるように、検体スライドの裏側に領域を囲むようにダイアモンドペン等でマークする。(4)検体スライドを72±1℃の変性溶液の入ったコプリンジャー中に浸漬し、検体スライドのDNAを変性する。(5)ピンセットを使って、検体スライドを変性溶液から取り出し、すぐに常温の70%エタノール中に入れる。ホルムアミドを除くためにスライドを振盪する。検体スライドを1分間浸漬する。(6)検体スライドを70%エタノールから取り出し、85%エタノール中に入れ、ホルムアミドを除くためにスライドを振盪する。検体を1分間浸漬する。100%エタノールで同じ操作を2回繰り返す。(7)ペーパータオルに検体スライドグラスの下端をつけてエタノールを取り除き、ペーパータオルでスライドグラスの裏側を拭く。(8)検体スライドをドライヤーで風乾または45~50℃のスライドウォーマーで2~5分間乾燥させる。
[Denaturation of sample slide DNA]
As the DNA denaturation treatment on the specimen slide, the following treatments (1) to (8) were performed on the specimen slide on which the specimen was fixed. (1) Preliminarily place a wet box (airtight container, taped on the side with a paper towel) placed in a 37 ° C incubator with a paper towel moistened with water before the specimen slide was created. Heat. (2) Make sure that the pH of the denaturing solution (70% formamide / SSC [150 mM NaCl, 15 mM sodium citrate]) is pH 7.0 to 8.0 at room temperature. The denaturing solution is placed in a coplinger and warmed in a hot tub until the solution is 72 ° C. ± 1 ° C. (placed in a 72 ± 1 ° C. hot tub for at least 30 minutes). (3) Mark with a diamond pen or the like so as to surround the area behind the specimen slide so that the part of the hybridization area can be identified. (4) The specimen slide is immersed in a copliner containing a denaturing solution at 72 ± 1 ° C. to denature the DNA on the specimen slide. (5) Using tweezers, remove the specimen slide from the denaturing solution and immediately place it in normal temperature 70% ethanol. Shake the slide to remove formamide. Immerse the specimen slide for 1 minute. (6) Remove the specimen slide from 70% ethanol, place it in 85% ethanol and shake the slide to remove formamide. Immerse the specimen for 1 minute. Repeat the same procedure twice with 100% ethanol. (7) Attach the lower end of the specimen slide glass to a paper towel to remove ethanol, and wipe the back side of the slide glass with a paper towel. (8) The specimen slide is air-dried with a dryer or dried with a slide warmer at 45-50 ° C. for 2-5 minutes.
 〔ハイブリダイゼーション〕
 上記変性処理を行った検体スライドに対して以下の(1)~(3)の処理をこの順で行うことで、検体スライドに対して上述したように調製したDNAプローブ10μL(10~50ng)を用いてハイブリダイゼーション処理を行った。(1)検体スライドのハイブリダイゼーション領域に調製した上記DNAプローブを10μL添加し、すぐに、22mm×22mmのカバーグラスをプローブの上に被せ均一にプローブを広げる。ハイブリダイゼーション領域に気泡が入らないようにする。(2)ペーパーボンドでカバーグラスをシールする。(3)前もって加温した湿潤箱に検体スライドを入れて蓋をして37℃のインキュベータで14~18時間ハイブリダイゼーションを行う。
[Hybridization]
By performing the following steps (1) to (3) in this order on the sample slide subjected to the above denaturation treatment, 10 μL (10 to 50 ng) of the DNA probe prepared as described above is applied to the sample slide. Hybridization treatment was carried out using this. (1) Add 10 μL of the prepared DNA probe to the hybridization area of the specimen slide, and immediately cover the probe with a 22 mm × 22 mm cover glass to spread the probe uniformly. Prevent bubbles from entering the hybridization area. (2) Seal the cover glass with a paper bond. (3) Place the specimen slide in a pre-warmed moist box, cover it, and perform hybridization in a 37 ° C. incubator for 14 to 18 hours.
 〔スライドグラスの洗浄〕
 上記ハイブリダイゼーション処理を行った検体スライドに対して以下の(1)~(6)の処理をこの順で行うことで、検体スライドの洗浄処理を行った。(1)ポストハイブリダイゼーション洗浄緩衝液(2×SSC/0.3%NP-40)をコプリンジャーに入れる。ポストハイブリダイゼーション洗浄緩衝液が72℃±1℃になるまで温浴槽で予備加熱をする(72℃±1℃の温浴槽に少なくとも30分間置く)。(2)ポストハイブリダイゼーション洗浄緩衝液を入れたコプリンジャーをもうひとつ用意し、常温に維持する。(3)ピンセットでペーパーボンドのシールを取り除く。(4)検体スライドをポストハイブリダイゼーション洗浄緩衝液の中に入れる。カバーグラスは自然に溶液中で剥がれるのを待つ。(5)溶液から検体スライドを取り出し、余分な溶液を取り去り、72±1℃に加温したポストハイブリダイゼーション洗浄緩衝液に2分間浸す。ここで、73℃を超える温度や処理時間として2分を超えないようにするのが望ましい。(6)コプリンジャーから検体スライドを取り出し、遮光下(締め切った引出や締め切ったキャビネットの棚等)で風乾する。
[Washing of slide glass]
By performing the following steps (1) to (6) in this order on the sample slide subjected to the above hybridization treatment, the sample slide was washed. (1) Add the post-hybridization wash buffer (2 × SSC / 0.3% NP-40) to the copliner. Preheat in a hot tub until the post-hybridization wash buffer is 72 ° C. ± 1 ° C. (place in a 72 ° C. ± 1 ° C. hot tub for at least 30 minutes). (2) Prepare another coplinger containing the post-hybridization washing buffer and keep it at room temperature. (3) Remove the paper bond seal with tweezers. (4) Place the specimen slide in the post-hybridization wash buffer. Wait for the coverglass to spontaneously peel off in solution. (5) Remove the specimen slide from the solution, remove the excess solution, and immerse in a post-hybridization wash buffer heated to 72 ± 1 ° C. for 2 minutes. Here, it is desirable not to exceed 2 minutes as the temperature exceeding 73 ° C. or the processing time. (6) Remove the specimen slide from the copliner and air dry under light shielding (closed drawer, closed cabinet shelf, etc.).
 〔DAPI染色〕
 DAPI染色は以下のように行った。まず、10μLのDAPI対比染色液を検体スライドのハイブリダイゼーション領域に添加した。次に、ハイブリダイゼーション処理した後、細胞数をカウントするためにDAPI染色(2μg/mLPBS)を25℃、10分間行うことで細胞核を染色し、カバーガラスを被せて、シグナルの計測まで検体スライドを遮光して保存した。DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride) はMolecular Probes社(D1306)を使用した。
[DAPI staining]
DAPI staining was performed as follows. First, 10 μL of DAPI counterstain was added to the hybridization area of the specimen slide. Next, after hybridization treatment, DAPI staining (2 μg / mL PBS) is performed at 25 ° C. for 10 minutes in order to count the number of cells. The cell nucleus is stained, covered with a cover glass, and the specimen slide is covered until signal measurement. Stored protected from light. DAPI (4 ′, 6-Diamidino-2-phenylindole, Dihydrochloride) used Molecular Probes (D1306).
 〔観察〕
 <蛍光顕微鏡観察>
 蛍光顕微鏡観察では、HER2遺伝子染色済み組織切片を、蛍光顕微鏡Zeiss imager(Camera:MRmモノクロ・冷却機能付、対眼レンズx10、対物レンズ×60油浸、Zeiss製フィルターセットHE46(励起フィルター500nm±12.5nm、ビームスプリッター515nm、蛍光フィルター535nm±15nm))にセットし、ハイブリダイズしたDNAプローブのアミノクマリン化合物内包樹脂粒子の蛍光発光を、蛍光画像(蛍光静止画像)として取得した。
[Observation]
<Fluorescence microscope observation>
In the fluorescence microscope observation, the tissue section having been stained with the HER2 gene was subjected to fluorescence microscope Zeiss imager (Camera: MRm monochrome / with cooling function, eye lens x10, objective lens x60 oil immersion, Zeiss filter set HE46 (excitation filter 500 nm ± 12.5 nm, beam splitter 515 nm, fluorescence filter 535 nm ± 15 nm)), and fluorescence emission of aminocoumarin compound-containing resin particles of the hybridized DNA probe was obtained as a fluorescence image (fluorescence still image).
 得られた蛍光画像から輝点の数を計測した結果を表2に示す。計測された起点数に差があらわれたのは、比較例の場合には緑のバックグランド(ノイズ)の中から緑輝点(シグナル)を見つけ出すのが比較的困難であるのに対して、実施例の場合には高い輝度なのでノイズの影響を受けずに検出できるためである。
[実施例8~12]
 実施例8~12においては、アミノクマリン化合物Iの代わりにアミノクマリン化合物II~VIをそれぞれ用いたこと以外は実施例7と同様の方法で、アミノクマリン化合物内包樹脂粒子II~VIを作製した。
Table 2 shows the result of measuring the number of bright spots from the obtained fluorescence image. The difference in the number of measured starting points was observed in the comparative example, while it was relatively difficult to find the green bright spot (signal) from the green background (noise). This is because in the case of the example, since the luminance is high, detection can be performed without being affected by noise.
[Examples 8 to 12]
In Examples 8 to 12, aminocoumarin compound-encapsulating resin particles II to VI were prepared in the same manner as in Example 7 except that aminocoumarin compounds II to VI were used in place of aminocoumarin compound I, respectively.
 アミノクマリン化合物内包樹脂粒子II~VIを用いて、実施例7と同様に平均粒径測定、蛍光強度測定、FACSおよびFISHを行った。ただし、実施例10および11においては、FACSは行わなかった。結果を表2に示す。
[比較例5~8]
 比較例5~8においては、アミノクマリン化合物Iの代わりにアミノクマリン化合物i~ivをそれぞれ用いたこと以外は実施例7と同様の方法で、アミノクマリン化合物内包樹脂粒子i~ivを作製した。
Using the aminocoumarin compound-encapsulating resin particles II to VI, the average particle size measurement, fluorescence intensity measurement, FACS, and FISH were performed in the same manner as in Example 7. However, FACS was not performed in Examples 10 and 11. The results are shown in Table 2.
[Comparative Examples 5 to 8]
In Comparative Examples 5 to 8, aminocoumarin compound-encapsulating resin particles i to iv were prepared in the same manner as in Example 7 except that aminocoumarin compounds i to iv were used instead of aminocoumarin compound I, respectively.
 アミノクマリン化合物内包樹脂粒子i~ivを用いて、実施例7と同様に平均粒径測定、蛍光強度測定、FACSおよびFISHを行った。結果を表3に示す。表3に示したFACSの結果より、比較例6~8では、蛍光色素がスルホン化されているにもかかわらず、ヒストグラムが比較例5のヒストグラムからそれほどシフトしていないことがわかる。 Using the aminocoumarin compound-encapsulating resin particles i to iv, the average particle diameter measurement, fluorescence intensity measurement, FACS and FISH were performed in the same manner as in Example 7. The results are shown in Table 3. From the FACS results shown in Table 3, it can be seen that in Comparative Examples 6 to 8, the histogram is not so shifted from the histogram of Comparative Example 5 even though the fluorescent dye is sulfonated.
Figure JPOXMLDOC01-appb-T000024
Figure JPOXMLDOC01-appb-T000024
Figure JPOXMLDOC01-appb-T000025
Figure JPOXMLDOC01-appb-T000025

Claims (7)

  1.  下記式(1)で示される構造を有するアミノクマリン化合物。
    Figure JPOXMLDOC01-appb-C000001
    (式(1)中、Rは、それぞれ独立に水素原子またはメチル基を表わし、Qはイオウ原子、酸素原子またはN-R1を表わし、R1は水素原子またはメチル基を表わす。)
    An aminocoumarin compound having a structure represented by the following formula (1).
    Figure JPOXMLDOC01-appb-C000001
    (In formula (1), each R independently represents a hydrogen atom or a methyl group, Q represents a sulfur atom, an oxygen atom or N—R 1 , and R 1 represents a hydrogen atom or a methyl group.)
  2.  前記式(1)中のQがイオウ原子である請求項1に記載のアミノクマリン化合物。 The aminocoumarin compound according to claim 1, wherein Q in the formula (1) is a sulfur atom.
  3.  前記式(1)中のQが酸素原子である請求項1に記載のアミノクマリン化合物。 The aminocoumarin compound according to claim 1, wherein Q in the formula (1) is an oxygen atom.
  4.  前記式(1)中のQがN-R1である請求項1に記載のアミノクマリン化合物。 The aminocoumarin compound according to claim 1 , wherein Q in the formula (1) is NR 1 .
  5.  請求項1に記載のアミノクマリン化合物と該アミノクマリン化合物を内包する樹脂粒子とを有するアミノクマリン化合物内包樹脂粒子。 An aminocoumarin compound-encapsulating resin particle comprising the aminocoumarin compound according to claim 1 and resin particles encapsulating the aminocoumarin compound.
  6.  前記樹脂粒子がアミノ樹脂粒子である請求項5に記載のアミノクマリン化合物内包樹脂粒子。 The aminocoumarin compound-encapsulating resin particles according to claim 5, wherein the resin particles are amino resin particles.
  7.  励起スペクトル極大波長が475~510nmであり、蛍光スペクトル極大波長が510~540nmである請求項5または6に記載のアミノクマリン化合物内包樹脂粒子。 The aminocoumarin compound-encapsulating resin particles according to claim 5 or 6, wherein the excitation spectrum maximum wavelength is 475 to 510 nm and the fluorescence spectrum maximum wavelength is 510 to 540 nm.
PCT/JP2017/005284 2017-02-14 2017-02-14 Aminocoumarin compound, and aminocoumarin compound-containing resin particles WO2018150450A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PCT/JP2017/005284 WO2018150450A1 (en) 2017-02-14 2017-02-14 Aminocoumarin compound, and aminocoumarin compound-containing resin particles
US16/477,433 US11434376B2 (en) 2017-02-14 2018-02-13 Aminocoumarin compound, and aminocoumarin compound-containing resin particles
JP2018568516A JP7151489B2 (en) 2017-02-14 2018-02-13 Aminocoumarin compound and aminocoumarin compound-encapsulating resin particles
EP18754496.0A EP3553136A4 (en) 2017-02-14 2018-02-13 Aminocoumarin compound, and aminocoumarin compound-containing resin particles
PCT/JP2018/004803 WO2018151072A1 (en) 2017-02-14 2018-02-13 Aminocoumarin compound, and aminocoumarin compound-containing resin particles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2017/005284 WO2018150450A1 (en) 2017-02-14 2017-02-14 Aminocoumarin compound, and aminocoumarin compound-containing resin particles

Publications (1)

Publication Number Publication Date
WO2018150450A1 true WO2018150450A1 (en) 2018-08-23

Family

ID=63169725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/005284 WO2018150450A1 (en) 2017-02-14 2017-02-14 Aminocoumarin compound, and aminocoumarin compound-containing resin particles

Country Status (1)

Country Link
WO (1) WO2018150450A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021182228A1 (en) * 2020-03-10 2021-09-16 コニカミノルタ株式会社 Light-emitting pigment-containing particle, method for producing same, and labeling agent for pathological diagnosis using same

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5069380A (en) * 1970-06-20 1975-06-10
JPH069892A (en) * 1992-06-22 1994-01-18 Nippon Kanko Shikiso Kenkyusho:Kk Coumarin derivative
JPH06271599A (en) * 1993-01-29 1994-09-27 Bayer Ag Sulfocoumarin-containing nucleotides and their use in detection of nucleic acid
JPH07508309A (en) * 1992-05-13 1995-09-14 モレキュラー・プロウブズ・インコーポレーテッド Fluorescent microparticles with controllable enhanced Stokes shift
JPH08259832A (en) * 1995-03-17 1996-10-08 Taoka Chem Co Ltd Ink for ink jet printing and printing of fabric using the same
JP2004309458A (en) * 2003-03-27 2004-11-04 Institute Of Physical & Chemical Research Time-resolved fluorescence microscope
JP2006045314A (en) * 2004-08-03 2006-02-16 Fuji Electric Holdings Co Ltd Salt composed of fluorescent anion and fluorescent cation and color conversion membrane using the same
JP2013147605A (en) * 2012-01-23 2013-08-01 Sumitomo Chemical Co Ltd Compound
JP2013227552A (en) * 2012-03-29 2013-11-07 Sumitomo Chemical Co Ltd Compound
JP2013231165A (en) * 2012-04-04 2013-11-14 Sumitomo Chemical Co Ltd Colored curable resin composition
JP2014044419A (en) * 2012-07-31 2014-03-13 Sumitomo Chemical Co Ltd Colored curable resin composition
WO2015041157A1 (en) * 2013-09-17 2015-03-26 国立大学法人九州大学 Organic electroluminescence element

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5069380A (en) * 1970-06-20 1975-06-10
JPS51526A (en) * 1970-06-20 1976-01-06 Bayer Ag Okisazoriruukumarin no seizoho
JPH07508309A (en) * 1992-05-13 1995-09-14 モレキュラー・プロウブズ・インコーポレーテッド Fluorescent microparticles with controllable enhanced Stokes shift
JPH069892A (en) * 1992-06-22 1994-01-18 Nippon Kanko Shikiso Kenkyusho:Kk Coumarin derivative
JPH06271599A (en) * 1993-01-29 1994-09-27 Bayer Ag Sulfocoumarin-containing nucleotides and their use in detection of nucleic acid
JPH08259832A (en) * 1995-03-17 1996-10-08 Taoka Chem Co Ltd Ink for ink jet printing and printing of fabric using the same
JP2004309458A (en) * 2003-03-27 2004-11-04 Institute Of Physical & Chemical Research Time-resolved fluorescence microscope
JP2006045314A (en) * 2004-08-03 2006-02-16 Fuji Electric Holdings Co Ltd Salt composed of fluorescent anion and fluorescent cation and color conversion membrane using the same
JP2013147605A (en) * 2012-01-23 2013-08-01 Sumitomo Chemical Co Ltd Compound
JP2013227552A (en) * 2012-03-29 2013-11-07 Sumitomo Chemical Co Ltd Compound
JP2013231165A (en) * 2012-04-04 2013-11-14 Sumitomo Chemical Co Ltd Colored curable resin composition
JP2014044419A (en) * 2012-07-31 2014-03-13 Sumitomo Chemical Co Ltd Colored curable resin composition
WO2015041157A1 (en) * 2013-09-17 2015-03-26 国立大学法人九州大学 Organic electroluminescence element

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOOSSENS, KAREL ET AL.: "Accurate Diffusion Coefficients of Organosoluble Reference Dyes in Organic Media Measured by Dual-Focus Fluorescence Correlation Spectroscopy", ACS NANO, vol. 9, no. 7, 2015, pages 7360 - 7373, XP055535817 *
JUNG, HYO SUNG ET AL.: "Rationally Designed Fluorescence Turn-On Sensors: A New Design Strategy Based on Orbital Control", INORGANIC CHEMISTRY, vol. 49, 2010, pages 8552 - 8557, XP055535829 *
KOMATSU, KENSUKE ET AL.: "Development of an Iminocoumarin-Based Zinc Sensor Suitable for Ratiometric Fluorescence Imaging of Neuronal Zinc", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 129, 2007, pages 13447 - 13454, XP055535833 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021182228A1 (en) * 2020-03-10 2021-09-16 コニカミノルタ株式会社 Light-emitting pigment-containing particle, method for producing same, and labeling agent for pathological diagnosis using same

Similar Documents

Publication Publication Date Title
RU2505609C2 (en) Compositions and methods for hybridisation
JP7147724B2 (en) Staining agent for tissue staining, method for producing staining agent for tissue staining, and tissue staining kit containing staining agent for tissue staining
JP6091753B2 (en) Compositions and methods for performing hybridization by separate denaturation of samples and probes
CN107250346B (en) The manufacturing method of cell-preservation liquid and its utilization and cell-preservation liquid
US20200232019A1 (en) Improvements in or relating to cell analysis
CN107200718B (en) Compound, method and kit for detecting DNA G-quadruplex
WO2015141856A1 (en) Probe reagent and fish using probe reagent
CA2640464A1 (en) Method for combining immunostaining and fish using covalently binding fluorophores
CN112111267B (en) AIE probe for nucleic acid identification and preparation method and application thereof
JP2022530140A (en) Hybridization compositions and methods for preparing and using the compositions.
Zheng et al. Development of Blood‐Cell‐Selective Fluorescent Biodots for Lysis‐Free Leukocyte Imaging and Differential Counting in Whole Blood
CN104115003A (en) Method for detecting target particles
WO2018150450A1 (en) Aminocoumarin compound, and aminocoumarin compound-containing resin particles
JP7151489B2 (en) Aminocoumarin compound and aminocoumarin compound-encapsulating resin particles
JP6187170B2 (en) Fluorescent dye-containing resin particles, fluorescent dye-containing resin particle set for tissue multiple staining containing the fluorescent dye-containing resin particles, and tissue multiple staining method using the fluorescent dye-containing resin particles
JP6583011B2 (en) Method for washing immunostained slides using acidic aqueous solution
JPWO2018151071A1 (en) Fluorescent labeling method
KR102066344B1 (en) Novel fluorescent compound for labelling nucleic acids and the preparation method thereof
JP2017026375A (en) Method of encapsulating slide stained by fish method or immunostaining method using phosphor aggregate nanoparticle
JP6780657B2 (en) Method for producing dye-containing thermosetting resin particles
JP7371405B2 (en) Nucleic acid sample quality evaluation method
JP6447679B2 (en) Fluorescent dye-containing resin particles and fluorescent dye-containing resin particle set for tissue multiple staining containing the fluorescent dye-containing resin particles
CN107312838A (en) Cell fluorescence in-situ hybridization method
CA2283094A1 (en) Detection of targets with green fluorescent protein and fluorescent variants thereof
KR102150803B1 (en) Novel fluorescent compound for analyzing complete blood cell and the preparation method thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17896770

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17896770

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP